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THE ROLE OF NF-κB ACTIVATION IN HEPATIC TUMOR PROMOTION BY 
POLYCHOLORINATED BIPHENYLS (PCBs)  
 
 
Polychlorinated biphenyls (PCBs) are nongenotoxic hepatic tumor promoters. 
PCBs have been shown to cause oxidative stress, but the exact mechanism by which 
PCBs exert their tumor promoting activity is not clear. In our study, PCB-153, a non-
coplanar congener, caused a transient increase in hepatic NF-κB DNA binding activity 
and cell proliferation, while PCB-77, a coplanar congener, showed no effect. Our second 
study using a mouse model that was deficient in the p50 subunit of NF-κB (p50-/-) 
showed that NF-κB contributes to the changes in hepatocyte proliferation and apoptosis 
in response to PCB-153 treatment: a single dose of PCB-153 increased hepatic NF-κB 
activity and cell proliferation in wild type mice, but not in the p50-/- mice; longer-term 
treatment with PCB-153 increased cell proliferation in p50-/- mice, but this increase was 
less than that in the wild type. In addition, p50-/- livers had more apoptosis than in the 
wild type, and PCB-153 inhibited apoptosis in the p50-/- livers. p50-/- livers had less 
cyclin D1 protein than the wild type, but that the mRNA levels were same. Bcl-xL protein 
was not changed by PCB-153, and wild type and p50-/- mice had the same level of Bcl-
xL protein. In the third study, PCB-77 caused an increase in hepatic NF-κB DNA binding 
 
activity and cell proliferation during the promotion stage, and this increase was blocked 
by dietary supplementation of vitamin E, but the number and volume of placental 
glutathione S-transferase (PGST)-positive foci were slightly, though insignificantly, 
increased in the same animals. The apparent conflict could be due to different effect in 
different cells: high level vitamin E significantly inhibited PCB-77-induced cell 
proliferation in normal hepatocytes, while this inhibitory effect was much less in the 
PGST-positive hepatocytes. In conclusion, our studies show that a non-coplanar PCB can 
cause an increase in hepatic NF-κB DNA binding activity in rats and mice, and this 
increase contributes to the change in cell proliferation and apoptosis. Dietary vitamin E 
supplementation did not show protective effect on the formation of altered hepatic foci 
that were promoted by PCBs, although vitamin E supplementation decreased PCBs-
induced hepatic NF-κB activation and cell proliferation. 
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Chapter 1. Introduction 
 
l. Introduction to Polychlorinated Biphenyls 
A. Background: 
 Polychlorinated biphenyls (PCBs) are a family of chemicals sharing a basic 
shape: a biphenyl ring structure with one to ten chlorine atoms placed in any of ten open 
positions on the ring structure. Therefore, there are 209 possible congeners or isomers of 
PCBs (Safe 1994).   
 Most PCB congeners are colorless, odorless crystals. The commercial mixtures 
are clear viscous liquids. PCBs have low water solubilities and low vapor pressures, 
while they are soluble in most organic solvents, oils, and fats. PCBs usually are very 
stable and do not degrade easily, and they can be destroyed only under certain conditions 
by chemical, thermal, and biochemical processes. Usually the processing of PCB waste 
requires high temperatures.  
 
B. Production of Polychlorinated Biphenyls: 
 PCBs were first synthesized by Schmidt and Schulz in 1881, but industrial 
production was not started until 1920’s. The industrial production of PCBs consisted of 
multiple congener mixtures and was sold under different brand names. In the United 
States, PCBs were produced by the Monsanto Chemical Company under the name 
“Aroclor”, and had individual production groups labeled as 1221, 1232, 1242, 1248, 1254 
and 1260, in which the last two digits represent the percentage of chlorine by weight in 
the mixture. PCBs were also produced and sold under different trade name in other 
countries, including Germany (Bayer, Clophens), France (Prodelec, Phenoclors), Italy  
(Caffro, Fenoclors), Japan (Kanegafuchi, Kanechlors), Russia (Sovol, Sovol), Poland 
(Zabkowice Slaskie, Chlorofen), Spain (Cross, Fenochlors) and Czechoslovakia 
(Chemko, Delor). Their production was banned in North America and Western Europe in 
the 1970’s, and in Eastern Europe and Russia in the 1990’s. The overall production of 
PCBs mixtures worldwide has been determined as 1.2 million metric tons, and the United 
States accounted for 35% of the world distribution of PCBs (Safe 1994). 
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PCBs have been used extensively in many industrial settings because of their 
stability under a broad range of chemical, thermal and electrical conditions. They were 
used in transformers and capacitors, in the formulation of lubricating and cutting oils, in 
pesticides and flame retardants, and as plasticizers in paints, copying paper, adhesive, 
sealants and plastics. 
 
C. Environment Pollution: 
 Due to their physical properties, PCBs have been widely used since the 1920’s, 
but until the development of sensitive detection system their contamination in 
environment was not understood. PCBs were first detected as an environmental 
contaminant by a gas chromatography method in 1966 (Jensen et al. 1969). After that, 
studies have shown that PCBs are present in the environment worldwide in varying 
concentrations, but mostly are found at the pg/m3 level in the atmosphere, ng/kg in 
surface water, and µg/kg in sediment and soils (Booij & van Drooge 2001; Fromberg et 
al. 1999; Hansen 2000; Rosinska & Sulkowski 2001). 
 Because of their lipophilicity and stability, PCBs bioconcentrate and 
bioaccumulate in the food chain, which has been demonstrated by the observation that 
high levels of PCBs concentration were found in fish fat and eggs of aquatic birds (in the 
mg/kg range) (Giesy et al. 1995; Giesy et al. 1994). 
 
D. PCBs exposure: 
 Humans are exposed to PCBs through inhalation of airborne particles, 
occupational exposure, and ingestion of food containing PCBs. Workers employed at 
transformer and capacitor manufacturing plants are among those most often exposed to 
PCBs through their occupation. The general public is exposed to PCBs from inhalation of 
particulates, or ingestion of contaminated food. The sources of food contamination 
include food packaging, crops grown on contaminated soil, contaminated feed for 
animals, or seafood from environmentally contaminated regions. The increased level of 
PCBs have been found in human serum, blood, adipose tissue, and human milk and milk 
fat; all these may due to the different routes of human exposure to PCBs (Safe 1994; 
Silkworth & Brown 1996). In addition, there are two significant PCB poisoning of 
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humans, the Yusho and Yucheng incidents, which occurred in Japan and Taiwan 
respectively. 
 
Yusho and Yucheng incidents: 
 In 1968, a mass food poisoning occurred in western Japan, involving more than 
1,850 people. The poisoning is now understood to have been caused by ingestion of a 
commercial brand of rice oil (Yusho) contaminated with polychlorinated derivatives of 
biphenyls, dibenzofurans, quaterphenyls, and some other related compounds. This 
poisoning caused acute toxicity including chlorance and skin pigmentation alteration, 
irritation of the eyes as well as increased discharge, fever, jaundice, headache, numbness 
in the limbs, general fatigue and weakness, as well as liver dysfunction (Okumura 1984). 
Epidemiological studies following this population showed offspring having darkly 
pigmented skin that faded by the age of five months (Yamashita & Hayashi 1985), and 
adults having respiratory distress, with major chlorance subsiding after about fifteen 
years (Nakanishi et al. 1985). An increased incidence of hepatocellular carcinoma has 
been linked to the PCB exposure in this population (Kikuchi 1984).  
  In 1979, an outbreak of food poisoning occurred in Taiwan, involving more than 
2,000 people. The event was also caused by ingestion of PCBs mixtures-contaminated 
rice oil (Yucheng). The symptoms observed in this population were similar to those seen 
in the Yusho incident, including skin diseases, liver damage, immunosuppression, and 
neuropathy (Ikeda 1996). The serum levels of PCBs in women of this population were 
still above average after 14 years (Guo et al. 1997). Chronic toxicity that has been 
attributed to PCB in this population includes reproductive dysfunction, liver and lung 
cancer (Guo et al. 1999; Ikeda 1996; Yu et al. 1997).  
 
Occupational exposure: 
 Studies have examined individuals who were exposed to PCBs during their 
employment years, mainly in those who ever worked in capacity and transformer plants. 
Studies on the adverse effects of PCBs on groups of occupational exposed workers have 
shown effects such as chloracne and dermal lesions, decrease in pulmonary function, 
decrease in body weight in children from exposed mother, eye irritation, and liver 
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dysfunction including hepatomegaly, increased liver enzymes, and induction of drug-
metabolizing enzymes (Safe 1994). Generally no increased mortality was ever found in 
those workers, although there was a link between PCB exposure and malignant 
melanoma and cancer of the brain (Sinks et al. 1992), and between PCBs exposure and 
pancreatic cancer (Yassi et al. 1994).  
 
General public exposure: 
 Due to their non-polar, lipophilic physical properties and their resistance to 
biochemical degradation, PCBs tend to accumulate in fatty tissues in humans. PCB levels 
in human have been studied for over 30 years. The general conclusions of PCBs in 
human are that PCBs are ubiquitous, with average levels in adipose around ppm level 
(Aronson et al. 2000; Hansen 2000; Safe 1994), and in blood around ppb levels (Hansen 
2000; Hunter et al. 1997). Not all humans have the same level of PCB in their body, 
because of different exposure levels from food, occupation, environment, and other 
sources.    
 
2. PCBs and cancer 
A. Summary of studies on PCBs and specific types of cancer 
Although studies showed no increase in overall mortality rate in the PCBs-
exposed groups, accumulating data have shown the association of PCBs exposure and 
specific types of tumors in human and experimental animals.  
 
Epidemiological studies 
PCBs and brain cancer 
 There was only one study describing the possible association of cancer of the 
brain and nervous system and PCBs exposure (Sinks et al. 1992). Although the brain 
cancer mortality was 2.5 fold higher than expected in the study group of electrical 
capacitor manufacturing workers, the possibility that the increased incidence of brain 
cancer is due to chance, bias, and confounding factor cannot be excluded in this study.  
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PCBs and breast cancer 
 The possible role of PCBs in breast cancer development has drawn much attention 
recently. Low chlorinated PCBs and some hydroxylated metabolites display estrogenic 
properties (Arcaro et al. 1998; Arcaro et al. 1999; Bonefeld-Jorgensen et al. 2001; 
Connor et al. 1997; Fielden et al. 1997; Gierthy et al. 1997; Kramer et al. 1997; Krishnan 
& Safe 1993; Nesaretnam & Darbre 1997; Ramamoorthy et al. 1999; Ramamoorthy et al. 
1997; Shekhar et al. 1997).  Mono- and non-ortho substituted PCB congeners share some 
structure similarities with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and can bind to 
the aryl hydrocarbon (Ah) receptor. Dioxin-like compounds elicit a broad spectrum of 
antiestrogenic activities and may reduce breast cancer risk; the interaction between 
AhR/ARNT and the estrogen response element (ERE) has been proposed to be at least 
partially responsible for this antiestrogenic effect by AhR (Klinge et al. 1999). On the 
other hand, activation of the Ah receptor leads to induction of CYP1A1/2 and CYP1B1 
expression, which in turn could increase the biotransformation of estradiol to catechol 
estrogens, the latter exhibiting genotoxic effects. Di-ortho-substituted congeners induce 
CYP2B1/2 and CYP3A4, similar to the activity of phenobarbital, and those enzymes are 
also involved in the metabolism of estradiol.  
 Most of epidemiological studies failed to show any association between exposure 
to total PCBs and breast cancer risk (Aronson et al. 2000; Davidson 1998; Dorgan et al. 
1999; Helzlsouer et al. 1999; Holford et al. 2000; Hunter et al. 1997; Laden et al. 2001a; 
Laden et al. 2001b; Liljegren et al. 1998; Lucena et al. 2001; Moysich et al. 1998; 
Moysich et al. 1999; Safe 1997; Ward et al. 2000; Wolff et al. 1993; Wolff et al. 2000; 
Zheng et al. 2000a; Zheng et al. 2000b), but recent studies suggested that exposure to 
specific congeners may be related to breast cancer. A case-control study showed that 
exposure to dioxin-like PCBs (PCB 105, 118, and 156) increased breast cancer risk 
(Demers et al. 2002), but another study showed the opposite results, in which PCB-156 
had a protective effect, while phenobarbital-like PCB-180 and –183 increased breast 
cancer risk (Holford et al. 2000).  
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PCBs and liver cancer 
Although studies following the Yucheng population have shown an increase in 
mortality from chronic liver disease and cirrhosis (Hsieh et al. 1996; Yu et al. 1997), 
there is no direct evidence on PCBs-induced liver cancer from epidemiological studies. In 
the Yusho population, an increased incidence of hepatocellular carcinoma has been 
linked to the PCB exposure (Kikuchi 1984).  
 
PCBs and pancreatic cancer 
 There has been no animal study examining the possible association between PCBs 
and pancreatic cancer. One study examining a cohort of workers once employed at a 
transformer manufacturing plant showed significantly increased mortality from 
pancreatic cancer, while the overall cancer death was not significantly increased (Yassi et 
al. 1994). 
                         
PCBs and skin cancer 
 An epidemiological study of cancer mortality among 138,905 electric utility 
workers showed increased mortality from malignant melanoma with PCB exposure 
(Loomis et al. 1997).  Another epidemiological study showed a 4-fold increase in 
mortality from malignant melanoma in 3,588 electrical capacitor manufacturing workers 
with known PCB exposure (Sinks et al. 1992). 
Experimental animals studies 
 PCBs have been suggested to have tumor promoting activity during 
carcinogenesis since the early rodent carcinogenicity studies in 1970’s. Ito et al. found 
that coadministration of PCBs (Kanechlor 500) with benzene hexachloride (BHCs) in the 
diet produced more incidences of nodular hyperplasia and hepatocellular carcinoma than 
that produced by BHCs alone (Ito et al. 1973). Since that, the carcinogenicity of PCBs 
has been studied extensively in a variety of organs of rats and mice.  
 
PCBs and breast cancer  
Nesaretnam et al. have shown a promoting or co-carcinogenic effect of PCBs in 
rat mammary carcinogenesis (Nesaretnam et al. 1998). Rats were injected with 3,3’4,4’-
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tetrachlorobiphenyl (PCB-77) following 7,12-dimethylbenz(a)anthracene (DMBA) 
initiation and then kept on diet containing PCB-77 for one week, rats were then kept on 
low- or high-fat diets with no PCB for 9 weeks. PCB-77 increased the number and 
incidence of mammary tumor, with the highest effect in animals fed a high fat diet. 
 
PCBs and liver cancer 
1. PCBs and liver tumor   
The role of PCBs mixture or specific congeners in liver carcinogenesis has been 
studied extensively in rats and mice (Glauert 2001; Safe 1994; Silberhorn et al. 1990). 
The general view of PCB mixtures or congeners is that either of them can act as tumor 
promoters by increasing the number of tumor or by inducing clonal expansion of 
spontaneously or chemically initiated cells to form preneoplastic lesions.  
Ito et al. demonstrated an enhanced tumor development in liver by PCBs when 
they were coadministrated with known hepatic carcinogen benzene hexachlorides 
(BHCs) (Ito et al. 1973). In the following studies, Nishizumi showed that administration 
of PCBs (Kanechlor-500) following treatment with hepatic carcinogen diethylnitrosamine 
(DEN) resulted in earlier appearance of tumors and a significant increase in the number 
of tumors (Nishizumi 1976). Study results did not show an acceleration of tumor growth.  
Using a modified protocol including a partial hepatectomy (PH) three weeks after 
initiation by N-2-fluorenylacetamide (2-FAA), Tatematsu et al. showed an enhancing 
effect on induction of hyperplastic liver nodules by the co-administration of 2-FAA and 
PCBs (500 or 1000 ppm) in male F344 rats (Tatematsu et al. 1979). It was shown that 2-
FAA or PH alone, or PCBs plus PH did not induce hyperplastic liver nodules, but 2-FAA 
plus PCBs significantly increased the number and total area of hyperplastic nodules. PH 
in the protocol after initiation by 2-FAA increased the tumorigenesis more than protocols 
without PH.  
Using N-ethyl-N-hydroxyethylnitrosamine (EHEN) as initiator, Hirose et al. 
showed that administration of PCB (0.05% in diet) for 32 weeks following initiation by 
EHEN significantly increased the incidence of hepatocellular carcinomas in male F344 
rats (Hirose et al. 1981). However, PCB failed to show any effect in renal carcinogenesis 
in the same study.  
 7
 
Preston et al. investigated the hepatic tumor promoting activity of Aroclor 1254, 
with DEN as the initiator (Preston et al. 1981). Administration of Aroclor 1254 (100 ppm 
in the diet) for 18 weeks following initiation significantly increased the incidence of 
hepatocellular carcinomas, while administration of Aroclor 1254 alone did not induce 
tumors. The removal of polychlorinated dibenzofuran (PCDF) impurity did not show any 
significant effect on the tumor promoting activity of Aroclor 1254.  
The tumor promoting activity of PCB (Aroclor 1254) in suckling Swiss mice was 
investigated (Anderson et al. 1983). Aroclor 1254 was administrated i.p. to pregnant 
mice, the suckling offspring of these mice and controls were treated with DEN. The DEN 
treatment caused liver tumors, and exposure to PCB significantly increased the incidence 
of liver tumors at the age of 18 months.  
Diwan et al. compared Aroclor 1254 to phenobarbital (PB) and 
dichlorodiphenyltrichloroethane (DDT) for their tumor promoting activities in D2B6F1 
male mice initiated with N-nitrosodiethylamine (NDE) (Diwan et al. 1994). At the test 
doses, Aroclor 1254 (175 and 350 ppm in diet) was more efficacious then PB (500 ppm 
in diet) or DTT (300 ppm in diet) at increasing the multiplicity of hepatocellular 
carcinomas, but did not affect the incidence or multiplicity of hepatoblastomas.  
 
2. Initiation/promotions studies using altered hepatic foci as marker 
 The ability of commercial PCB mixtures and individual congeners to initiate or 
promote the preneoplastic lesions has been studied using several different initiation-
promotion hepatocarcinogenic protocols. Altered hepatic foci (AHF) are the most used 
endpoints to quantify preneoplastic lesions, since the development of these biochemical 
markers has been correlated with the later development of malignant neoplasms (Pitot & 
Dragan 1994). The most commonly used foci in PCB studies are those deficient in 
ATPase and those that contain increased placental glutathione S-transferase (PGST) or γ-
glutamyl transpeptidase (GGT).       
Mixtures of PCBs 
 An early study using AHF as markers to determine the tumor promoting activity 
of PCB was done by Deml and Oesterle (Deml & Oesterle 1982). The administration of 
Clophen A 50 (50 or 100 mg/kg body wt/week for 7 weeks) to Sprague-Dawley rats 
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following initiation by DEN significantly increased the number and volume of ATPase-
deficient and GGT-positive foci, while Clophen alone only resulted in a small number of 
foci.  The tumor promoting activity of PCBs was shown to be sex dependent, and PCBs 
showed more potent tumor promoting activity in female rats than in male rats. Another 
study done by Pereira et al. demonstrated that a single dose of Aroclor 1254 (500 mg/kg) 
promoted GGT-positive foci in rat liver after a 2/3 partial hepatectomy (PH) and 
initiation by DEN (Pereira et al. 1982). 
 Oesterle and Deml further investigated the tumor promoting activity of the PCB 
mixture Clophen 50 in weanling Sprague-Dawley rats using N-nitrosamine as initiator 
(Oesterle & Deml 1983).  Administration of Clophen 50 (100 mg /kg of body weight, 
once a week for 1-7 weeks) following initiation caused an early appearance and increased 
number and total volume of ATPase-deficient and glycogen- and GGT-positive foci, 
while Clophen 50 alone caused few foci.  The same group (Deml and Oesterle) observed 
a dose-dependent tumor promoting activity of Clophen A50 in weanling female Sprague-
Dawley rats initiated with DEN (Deml & Oesterle 1987). Different levels of Clophen 
A50 (0.1, 0.5, 1.0, 5 and 10 mg/kg of body weight, three times per week for 11 weeks) 
were given to rats after a single dose of DEN. The lowest effective dose of Clophen A50 
was shown to be 1 mg/kg body weight.  
Denk et al. demonstrated the dose dependent effect of the initiating agent on PCB 
promotion (Denk et al. 1990). The male and female Sprague-Dawley rats were initiated 
by 2-nitropropan vapors (0, 25, 40, 50, 80, and 125 ppm, 6 h/day, 5 days/week for 3 
weeks), and then were treated with Clophen A50 (10 mg/kg body weight, twice a week 
for 8 weeks). The number of ATPase-deficient foci was correlated with the dose of 2-
nitropropan. Also, a sex-dependent effect was observed in this study, female rats 
exhibited an approximately four times higher incidence of foci than male rats.  
Another initiating agent, aflatoxin B1 (AFB1), was used by Pelissier and 
coworkers to test the promoting activity of PCB mixture Phenoclor DP-6 (Pelissier et al. 
1992). After initiation by AFB1, male Sprague-Dawley rats were fed a diet containing 50 
ppm Phenoclor DP-6 for 11 days, and the number and volume of GGT-positive foci was 
increased by PCB administration.   
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Studies did not show any solid evidence that PCB mixtures could act as tumor 
initiator in liver. Pereira et al. showed that Aroclor alone did not initiate GGT-positive 
foci. Studies by Deml and Oesterle showed that PCB (Clophen) alone only resulted in a 
small number of foci, which could be the results of promotion of “spontaneous” foci or 
those initiated by “contaminants” in the PCB mixtures or diet.  
Individual PCB congeners 
 A number of studies addressed the initiation/promotion of AHF by individual 
PCB congeners. Preston et al. have shown that both 2,2’,5,5’-tetrachlorobiphenyl (PCB-
52) and 2,2’4,4’-tetrachlorobiphenyl (PCB-47) (100 ppm in diet for 27 weeks) promoted 
GGT-positive foci after initiation by PH and DEN (Preston et al. 1985).  
Kobusch et al. investigated the effects of 3,3’4,4’-tetrachlorobiphenyl (PCB-77) 
on the growth of glucose-6-phosphatase (G6Pase)-altered foci in B6C3F1 mice (Kobusch 
et al. 1989). Mice were initiated by N-nitrosomorpholine (NNM), and then received 
PCBs (five i.p. injections, 50 mg/kg body weight, every 3 days). The number of G6Pase-
negative and positive foci was decreased by PCB, while the mean volume of foci was 
increased as the result of an increase in the percentage of foci of large size. The tumor 
promoting activity of PCB-77 was tested in other several studies. The initiators used 
included DEN (Berberian et al. 1995; Buchmann et al. 1986; Buchmann et al. 1991; 
Sargent et al. 1991; Tharappel et al. 2002), NNM (Wolfle et al. 1988), and PH plus DEN 
(Sargent et al. 1991); the markers used included ATPase-deficient foci (Berberian et al. 
1995; Buchmann et al. 1986; Buchmann et al. 1991; Sargent et al. 1991; Wolfle et al. 
1988), GGT-positive foci (Berberian et al. 1995; Buchmann et al. 1991; Sargent et al. 
1991), and PGST-positive foci (Sargent et al. 1991; Tharappel et al. 2002). Data from all 
these studies demonstrated a promoting activity of PCB-77 on the growth of AHF.  
A study of different PCB congeners, based on their ability to induce cytochrome 
P450, found that both a phenobarbital (PB)-type inducer (2,2’4,4’,5,5’-
hexachlorobiphenyl, PCB-153) and a 3-methylcholanthrene (3-MC)-type inducer 
(3,3’4,4’-tetrachlorobiphenyl, PCB-77) promoted ATPase-deficient focal lesion in female 
Wistar rats initiated with DEN (Buchmann et al. 1986). PCB-77 was more potent than 
PCB-153 in this study, although PCB-153 is poorly metabolized and thus has a long half-
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life in the body, while PCB-77 is just the opposite. In this case, the persistence of a PCB 
did not determine its tumor promoting capacity.  
Other studies on PCB-153 also show its promoting activity.  Hemming et al. 
showed that PCB-153 (1000, 5000, or 20,000 µg/kg/week s.c. for 20 weeks) enhanced 
GGT-positive and PGST-positive focal lesions after initiation with PH and DEN 
(Hemming et al. 1993).  PCB-153 has also been shown to promote PGST-positive focal 
lesion after initiation with a single dose of DEN (Berberian et al. 1995; Tharappel et al. 
2002); the dose of PCB-153 used in both studies was 4 i.p. injections of 300 µmol/kg 
body weight every other week.  
Other PCB congeners which have been studied include 4-chlorobiphenyl 
(Buchmann et al. 1991), 2,2’4,5’-tetrachlorobiphenyl (PCB-49) (Buchmann et al. 1991), 
2,3,3’4,4’-pentachlorobiphenyl (PCB-105) (Haag-Gronlund et al. 1998; Hemming et al. 
1993), 2,3,4,4’,5- pentachlorobiphenyl (PCB-114) (Buchmann et al. 1991), 2,3’,4,4’,5- 
pentachlorobiphenyl (PCB-118) (Haag-Gronlund et al. 1997b; Haag-Gronlund M 2000), 
3,3’,4,4’,5-pentachlorobiphenyl (PCB-126) (Dean et al. 2002; Haag-Gronlund et al. 
1998; Haag-Gronlund et al. 1997b; Hemming et al. 1995; Hemming et al. 1993), and 
2,3,3’,4,4’,5-hexachlorobiphenyl (PCB-156) (Haag-Gronlund et al. 1997a). All PCB 
congeners tested, except 4-chlorobiphenyl, have been shown to promote the growth of 
AHF.  
The interactive effects between different PCBs have been investigated by co-
administration of two PCBs together. Sargent et al. examined the separate and combined 
effect of non-coplanar 2,5,2',5'-tetrachlorobiphenyl (PCB-52) and coplanar 3,4,3',4'-
tetrachlorobiphenyl (PCB-77) (Sargent et al. 1991). Rats were initiated with PH/DEN 
and then were fed the PCBs for one year. PCB-77 alone (0.1 ppm in diet) following 
initiation did not increase the number or volume of AHF, while PCB-52 (10 ppm in diet) 
increased the volume but not the number of AHF. The co-administration of the two 
PCBs, however, synergistically increased both the number and volume of PGST-positive 
and ATPase-negative focal lesions. Haag-Grolund and coworkers examined the 
interactive effects between a non-ortho substituted PCB (PCB-126), a mono-ortho 
substituted PCB (PCB-105), and a both-ortho substituted PCB (PCB-153) (Haag-
Gronlund et al. 1998). In this study, rats were initiated with PH/DEN and then fed 15 
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systematically select dose combinations of PCBs for 20 weeks. No synergistic effects 
were observed in this study. An additive effect was observed between PCB-105 and 
PCB-153, while antagonistic effects were observed between PCB-126 and PCB-153, and 
between PCB-126 and PCB-105, respectively. Berberian et al. investigated the 
interactive effects between PCB-77 and PCB-153 (Berberian et al. 1995). In this study, 
each PCB was given to rats at a dose of 300 µmol/kg every two weeks for four injections, 
or 150 µmol/kg each for the combination of two PCBs, after a single dose of DEN. The 
co-administration of PCB-153 decreased the volume and number of foci induced by 
PCB-77. The same results were observed in a study using the similar protocol (Tharappel 
et al. 2002), in which the rats were initiated with a single dose of DEN and then received 
4 i.p. injections of PCB-77 (100 or 300 µmol/kg) or PCB-153 (100 or 300 µmol/kg), or 
both PCBs (100 µmol/kg each) every two weeks. Both PCB-77 and PCB-153 increased 
the number and volume of PGST-positive foci, and antagonistic effects were observed 
between the two PCBs. van der Plas et al. compared the tumor promoting capacity of a 
mixture of polyhalogenated aromatic hydrocarbon (PAHs) with and without PCB-153. 
The PAH mixture contained 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 1,2,3,7,8-
pentachlorodibenzo-p-dioxin (PeCDD), 2,3,4,7,8-pentachlorodibenzofuran (PeCDF), 
PCB-118, PCB-156, and PCB-126. The rats were initiated with PH/DEN and then were 
promoted by s.c. injections of PAH mixtures with and without PCB-153 (once a week for 
20 weeks). The addition of PCB-153 slightly but insignificantly increased the mean focal 
volume and the volume fraction of PGST-positive foci. A recent study demonstrated an 
antagonistic effect between PCB-126 and PCB-153 (Dean et al. 2002), in which the 
female F344 rats were treated with a single i.p. injection of DEN followed by PH and by 
oral administrations of PCB126 (0.1, 1.0 and 10 µg/kg body weight) or PCB-153 (10, 
100, 1000, 5000, and 10000 µg/kg body weight), or the combination of two PCBs (0.1 + 
10, 1 + 100, 10 + 1000, 10 + 5000, and 10 + 10000 µg/kg body weight) 3 times weekly 
for 6 weeks. Each PCB alone caused a dose dependent increase in the number and 
volume of PGST-positive foci, while treatment with the mixture of two PCBs resulted in 
an antagonistic PGST-positive focal formation at all dose combinations. 
Based on all studies, we can draw a few conclusions on the roles of PCBs in liver 
carcinogenesis. Both PCB mixtures and individual congeners have tumor promoting 
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activity; the PCB congeners include coplanar PCBs (PCB-77 and PCB-126), di-ortho 
substituted PCBs (PCB-47, PCB-49 and PCB-153), and mono-ortho substituted PCBs 
(PCB-105, PCB-114, PCB-118, and PCB-156), but a lower chlorinated PCB (4-
chlorobiphenyl) is a poor promoter. DEN is the most common used initiator in the 
promotion study of PCB in rodent livers, but other initiating agents used include NNM 
and aflatoxin B1. Generally, there is no synergistic effect between PCB congeners.   
  
PCBs and lung cancer 
 PCBs mixtures and specific congeners have been shown to promote lung tumor 
formation in rodents. The first evidence of PCBs as a lung tumor promoter was shown by 
Anderson et al., in which a single dose of Aroclor 1254 significantly increased the 
incidence of lung tumors (alveologenic adenomas) in N-nitrosodimethylamine (NDMA)-
initiated infant mice, while Aroclor alone had no effect (Anderson et al. 1986). In the 
following study by the same group, 2,2’,3,4,4’,5’-hexachlorobiphenyl , an Ah-receptor 
agonist, promoted lung tumors in NDMA-initiated infant mice, while 2,2’,4,4’,5,5’- 
hexachlorobiphenyl, did not show promoting activity (Anderson et al. 1991).  Aroclor 
1254 showed a promoting activity on lung tumor formation in NDMA-initiated mice 
(Anderson et al. 1994). 
 The specific sex and initiator-related differences in PCBs-induced lung 
tumorigenesis have been investigated. Aroclor 1254 increased the incidence of lung 
tumors initiated transplacentally by NDMA or 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) in male mice (Beebe et al. 1993), but not in female mice. In mice 
initiated neonatally, Aroclor 1254 promoted NNK-initiated lung cancer in females, and 
NDMA-initiated lung cancer in males. Kanechlor-400 has been shown to promote 1-
nitropyrene-initiated lung tumorigenesis in mice (Nakanishi et al. 2001). 
One study showed the activation of ras oncogene by PCBs (Ramakrishna & 
Anderson 1998). In this study Aroclor 1254 affected the level and membrane location of 
the K-ras p21 protein.  
One early study showed the protective effect of PCBs mixture Aroclor 1254 in 
lung cancer prior to NDMA treatment in mice (Anderson et al. 1983), but in the same 
study, Aroclor increased the NDMA-initiated liver cancer.     
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PCBs and skin cancer 
 Animal studies using 2,2’,5,5’-tetrachlorobiphenyl or 2,2’,5,5’-
tetrachlorobiphenyl 3,4-oxide failed to show promoting activity for these agents in mouse 
skin carcinogenesis (Preston et al. 1985), although they did show promoting activity for 
hepatic GGT-positive foci initiated with diethylnitrosamine.  
 
 In summary, both PCB mixtures and specific congeners have been demonstrated 
to have tumor promoting activities in liver and lung. There is very limited data on the 
relationship between PCB exposures and cancer in other organs.   
 
B. Mechanisms of PCBs as tumor promoter 
Induction of cytochrome P-450 by PCBs 
 PCBs as inducers of cytochrome P-450 mono-oxygenases have been studied 
extensively. PCB congeners can be divided into three categories based on their structure-
activity relationships. 
1. Co-planar PCB congeners 
Coplanar PCBs are PCB congeners that are substituted in both para and at least 
two meta positions but not in any of the ortho positions, they may form a coplanar 
configuration similar to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and bind strongly to 
Ah receptor. The toxic effects of coplanar PCBs include immunological and reproductive 
effects, the induction of a wasting syndrome, hepatic toxicities such as hepatimegaly, the 
induction of cytochrome P4501A1 and 1A2 (CYP1A1, CYP1A2) and carcinogenesis.  
2. Non-coplanar PCB congeners 
PCB congeners with chlorine substitutes in two ortho-positions are non-coplanar, 
have low affinity to Ah receptor; they induce the cytochrome P450 2B1 and 2B2 
(CYP2B1, CYP2B2), in a pattern similar to phenobarbital (PB), and some of them are 
neurotoxic (Fischer et al. 1998). The induction of CYP2B1 by the non-coplanar PCBs is 
mediated by the constitutive androstane nuclear receptor (CAR) (Muangmoonchai et al. 
2001). Like PB, these PCBs can have hepatic tumor promoting activity.  
3. Mixed-type PCB congeners 
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 Mixed-type PCB congeners are those which have the features of both coplanar 
and non-coplanar PCB congeners. Usually they contain only one ortho-substituted 
chlorine and they bind to the AhR at a lower affinity than do the coplanar PCB 
congeners.  
 
Liver carcinogenesis and tumor promoter 
Liver carcinogenesis can be divided into at least three consecutive phases: 
initiation, promotion, and progression (Dragan et al. 1993). The first step, initiation, 
results from a genetic change, which could be due to a chemical, physical, or microbial 
agent.  The genetic alteration is irreversible; however, the initiated phenotype is not fully 
expressed unless the cell is promoted, which is the second step of carcinogenesis. The 
promotion stage involves a reversible clonal expansion of single initiated cells. A fraction 
of hepatic focal lesions represent the precursor to hepatic cancer in the evolution of 
hepatocellular carcinoma. Progression is the final stage of carcinogenesis and occurs 
when a neoplasm develops into a benign or a malignant neoplasm. Tumor promoters are 
a group of compounds that can enhance the growth of hepatic focal lesions by changing 
cell proliferation and cell death. Tumor promoters, such as phenobarbital and peroxisome 
proliferators, do not interact directly with genomic DNA, but chronic administration of 
these compounds cause the increased incidence of hepatic tumors (Bayly et al. 1994; 
Cunningham 1996; Gill et al. 1998; Roberts et al. 1995; Shane et al. 2000). The exact 
mechanisms by which tumor promoters exert their promoting activities are still unknown. 
Mechanisms including an inhibition of apoptosis and induction of cell proliferation have 
been proposed for the change in growth of hepatic focal lesion caused by tumor 
promoters. The possible intermediate steps on the pathways for PCBs to 
hepatotumorigenicity were suggested to include PCBs accumulation in the liver, 
development of oxidative stress, and promotion of hepatic foci lesion growth. 
 
Reactive oxygen species and cancer 
 Reactive oxygen species (ROS) include superoxide anion, hydrogen peroxide, and 
the hydroxyl radical. ROS are generated in cells because of incomplete reduction of 
molecular oxygen to water during aerobic metabolism. Usually, cellular antioxidants and 
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the endogenous antioxidant enzymes inactivate ROS to maintain an intracellular 
reduction and oxidation (redox) balance. Inflammation, hyperoxia, ultraviolet (UV) and 
ionizing irradiation, and certain oxidant chemicals induce over-production of ROS. The 
generation of excess ROS has been proposed as a mechanism by which some xenobiotics 
produce cancer (Cerutti & Trump 1991; Huber et al. 1991; Hunt et al. 1998). Compounds 
can produce ROS through biotransformation into reactive intermediates and lead to 
genotoxic events such as DNA strand breaks or oxidative DNA damage (e.g. 8-
hydroxyguanosine). In addition to reacting with important macromolecules (lipids, 
proteins, DNA), ROS can stimulate changes in gene expression, such as the 
overexpression of c-fos, c-jun, and c-myc (Crawford 1990). The transcription factors 
activator protein 1 (AP-1) and nuclear factor-κB (NF-κB) are stimulated by ROS (Abate 
et al. 1990; Li & Karin 1999), which can lead to enhanced cell proliferation. Protein 
kinase C (PKC), another regulator of hepatocyte proliferation, also is stimulated by ROS 
(Das & White 1997). In addition, oxidative stress blocks gap junction intercellular 
communication, an important mechanism of tumor promotion and cell proliferation 
(Hotz-Wagenblatt & Shalloway 1993). 
 
Oxidative stress by PCBs 
Increased oxidative stress is one of mechanisms by which PCBs may exert their 
tumor promoting activity. PCBs cause increases in oxidative stress through a number of 
mechanisms. PCBs, especially the higher chlorinated congeners, selectively induce 
cytochrome P-450s (Parkinson et al. 1983) that may catalyze the oxidation of a broad 
range of endogenous and exogenous chemicals, including PCBs themselves. This 
induction of specific P-450 isozymes is through ligand-receptor interaction, including Ah 
receptor and CAR, as discussed before. In addition, non-coplanar PCBs also induce 
cytochrome P-450 3A genes through the pregnane X receptor (PXR) (Schuetz et al. 
1998). Reactive oxygen species (ROS) in the form of superoxide or hydrogen peroxide 
can “leak” out of the cytochrome P-450 system (Goeptar et al. 1995), which then 
increases the level of oxidative stress. For low chlorinated PCBs, their metabolism is 
mediated primarily through cytochrome P-450s, which catalyze the oxidation of 
chlorinated biphenyls to mono- and di-hydroxy metabolites. The di-hydroxy metabolites 
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can autoxidize or can be enzymatically oxidized into semiquinones and/or quinones 
(McLean et al. 1996); these quinone metabolites participate in redox cycling, with the 
formation of ROS, thus being a source of oxidative stress (McLean et al. 2000). 
Production of ROS by PCB dihydroxyl metabolites has been shown to increase the levels 
of DNA strand breaks (Srinivasan et al. 2001). The formation of ROS following PCBs 
exposure has been detected in cell-free systems (McLean et al. 1996; Oakley et al. 1996), 
in cell cultures (Slim et al. 2000), and in experimental animals (Dogra et al. 1988; 
Kamohara et al. 1984; Pelissier et al. 1990; Pereg et al. 2002; Saito 1990; Twaroski et al. 
2001a; Twaroski et al. 2001b). Biomarkers of PCBs-induced oxidative stress include 
lipid peroxidation (Kamohara et al. 1984; Pelissier et al. 1990; Peltola et al. 1994; Saito 
1990), DNA-single strand breaks (Srinivasan et al. 2001), a decrease in antioxidant 
defense (Schramm et al. 1985; Srinivasan et al. 2001; Twaroski et al. 2001b), and 
activation of the oxidative stress-sensitive transcription factors NF-κB and AP-1 
(Tharappel et al. 2002; Twaroski et al. 2001a). 
  Several studies have shown an increase in hepatic lipid peroxidation after PCBs 
exposure. The PCB mixture Kanechlor 500 (500 mg/kg diet for 5 months) caused an 
increase in hepatic thiobarbituric acid reactive substances (TBARS) (Kamohara et al. 
1984). Aroclor 1248 administration (100 mg/kg diet for 240 days) caused an increase in 
hepatic TBARS, and this increase was prevented by higher level of dietary vitamin E. 
Saito showed that the administration of PCB (0.05% in the diet for 10 days) caused an 
increase in the TBARS in liver homogenates as well as in the cytosolic, mitochondrial, 
and microsomal fractions, but not the nuclear fraction (Saito 1990). Yamamoto et al. also 
reported the increased TBARS in hepatic microsomal and mitochondrial fractions after 
PCB exposure (0.02% in the diet for 10 days), and this increase was prevented by dietary 
vitamin E (0.1 %) or probucol (Yamamoto et al. 1994). Dogra et al. examined the 
production of ethane and the concentration of hepatic malondialdehyde (MDA) in male 
Sprague Dawley rats after a single dose of Aroclor 1254 (500 mg/kg) or one of the three 
PCB congeners (300 µmol/kg): PCB-77, PCB-114, or PCB-153 (Dogra et al. 1988). 
Total ethane exhalation was increased during the 30-day period after Aroclor 1254 
administration, but this increase was due to an inhibition of ethane metabolism during the 
first two weeks, while it was due to increases in ethane production during the third and 
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fourth weeks. Hepatic MDA concentration was increased by Aroclor 1254 after 30 days, 
but not after 1, 3, 5, 7, or 14 days. Also, increases in hepatic MDA and ethane production 
rates were found 30 days after administration of single dose of one of three congeners.  
 Studies also showed that specific PCB congeners could cause increases in lipid 
peroxidation. Our lab recently found that hepatic TBARS concentration was increased 2, 
6, or 10 days after a single dose of either PCB-77 or PCB-153 (150 µmol/kg) in male 
Sprague Dawley rats (Fadhel et al. 2002). Recently, Hassoun et al. have shown that 13 
weeks exposure of PCB-126 produced dose-dependent increases in the production of 
superoxide anion, TBARS, and DNA single-strand break in rat hepatic and brain tissues 
(Hassoun et al. 2001). The same group reported the same increases in these biomarkers 
after 30 weeks of PCB-126 (Hassoun et al. 2002).  
 Lipid peroxidation may affect carcinogenesis through a number of mechanisms. 
The lipid peroxidation product 4-hydroxy-2-nonenal (HNE) can induce cell proliferation 
(Watanabe et al. 2001). Some of lipid peroxidation products, such as MDA, can react 
with DNA and thus are genotoxic (Basu & Marnett 1984; Benamira et al. 1995), and are 
carcinogenic in rats (Dedon et al. 1998). Also, cell proliferation and/or apoptosis could be 
affected by the oxidation products of polyunsaturated fatty acid could by acting on signal 
transduction pathways (Colquhoun & Schumacher 2001; Welsch 1995). 
 Another mechanism by which oxidative stress from PCB exposure could affect 
tumor promotion is through alterations in gene expression. The Ah receptor, CAR and 
PXR-dependent induction of cytochrome P-450 have already been discussed. In addition, 
the oxidative stress-sensitive transcription factor NF-κB may be involved in this pathway.  
 
NF-κB in liver carcinogenesis  
Recently, hepatic tumor promoters such as peroxisome proliferators, 
phenobarbital, and specific PCB congeners (PCB-77 and PCB-153) have been found to 
activate transcription factors (e.g. NF-κB) that regulate the expression of cell 
proliferation- and apoptosis-related genes (Li et al. 2000; Li et al. 1996a; Li et al. 1996b; 
Nilakantan et al. 1998; Tharappel et al. 2002).  The activation of NF-κB has been found 
to be mediated by active oxygen (Abate et al. 1990; Amstad et al. 1992; Schreck et al. 
1992), and NF-κB has been considered as a sensitive biomarker of oxidative stress (Li & 
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Karin 1999). Constitutive activation of NF-κB has been discovered in certain types of 
carcinoma (Dejardin et al. 1995; Sovak 1997; Tai et al. 2000). 
NF-κB is present in cytoplasm as an inducible heterodimer and usually consists of 
two subunits, a 50-kDa (p50) and a 65-kDa (p65) polypeptide that are complexed to an 
inhibitory subunit (IκB). Upon stimulation, IκB is phosphorylated, ubiquinated and 
degraded; NF-κB then can translocate into the nucleus, bind to the κB-binding site in 
promoter region of certain genes and alter gene expression. The role of NF-κB in cell 
growth and tumorigenesis has been studied extensively because of the ability of NF-κB 
to modulate transcription of genes whose products are involved in cell proliferation and 
suppression of apoptotic cascade. Among the NF-κB-regulated genes, cyclin D1 controls 
the cell cycle checkpoint at G1/S phase (Guttridge et al. 1999; Hinz et al. 1999). NF-κB 
is required for the initiation of cyclin D1 transcription and hyperphosphorylation of pRB, 
which lead cells to progress through G1 and entry into S phase (Biswas et al. 2000; 
Henry et al. 2000; Joyce et al. 1999; Kaltschmidt et al. 1999). The overexpression of 
cyclin D1 has been observed in hepatocellular carcinoma (HCC) (Joo et al. 2001); studies 
with transgenic mice model show that targeted overexpression of cyclin D1 leads to the 
development of mammary carcinomas (Wang et al. 1994) and hepatocellular carcinoma 
(Deane et al. 2001). Hepatocyte cyclin D1 expression can be increased by the hepatic 
tumor promoters nafenopin (Chevalier & Roberts 1999) and phenobarbital (Kinoshita et 
al. 2002), which suggests that changes in the cyclins/CDK complexes and their inhibitors 
could result in the loss of regulation of hepatocyte proliferation. 
Alteration of cell apoptosis is another mechanism by which non-genotoxic 
carcinogens may induce cancer. Dysregulation of apoptosis may result in the decreased 
ability of cell to undergo apoptosis and provide a selective survival advantage for those 
cells, thus leading to altered growth, cellular transformation and tumor progression. The 
balance between cell proliferation and death determines the fate of cells in 
hepatocarcinogenesis, such as cell growth and clonal expansion (Kolaja et al. 1996). 
Tumor promoters such as phenobarbital and WY-14,643 have been shown to reduce 
relative rates of cell death in both normal liver and hepatic neoplasia (Kolaja et al. 1996). 
Withdrawal of these tumor promoters resulted in regression of hyperplastic liver, 
preneoplastic foci, and adenomas with an increase in apoptosis. Besides, phenobarbital 
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has been shown to inhibit the spontaneous or transforming growth factor β1 (TGF-β1)-
induced apoptosis in primary hepatocyte culture and mouse liver (Sanders & 
Thorgeirsson 1999; Sanders & Thorgeirsson 2000). These studies indicate that apoptosis 
plays an important role in rodent hepatocarcinogenesis.  
The molecular targets involved in the regulation of apoptosis have been studied to 
elucidate the alteration of apoptosis during hepatocarcinogenesis. NF-κB regulates 
expression of certain anti-apoptotic genes, such as cIAPs (Wang et al. 1998) and Bcl-
2/Bcl-xL (Lee et al. 1999; Tamatani et al. 1999; Wang et al. 1999). Knockout studies 
revealed that the p65 subunit of NF-κB is essential for cell to survive the TNF-α induced 
apoptosis, because deficiency in p65 is embryonic lethal (Beg et al. 1995). Human and 
murine Bcl-xL promoters contain several κB-binding sites and the binding of NF-κB to 
the κB sites regulates the expression of Bcl-xL and the cell resistant to apoptosis 
(Khoshnan et al. 2000; Lee et al. 1999). Bcl-2/Bcl-xL locates in the outer membrane of 
mitochondrial and inhibits the release of cytochrome c; other members include apoptosis-
inducing protein (e.g. Bax and Bak) and inhibiting proteins (e.g. BAG-1). Bcl-2 family 
members have been found to be involved in the inhibition of apoptosis by tumor 
promoters, such as phenobarbital and WY-14,643, in primary hepatocyte and in mouse 
liver (Christensen et al. 1998; Christensen et al. 1999; Sanders & Thorgeirsson 2000).  
 All of these studies suggest that NF-κB could potentially contribute to the 
nongenotoxic carcinogen-induced carcinogenesis through increasing cell proliferation 
and inhibition of apoptotic cell death. 
 
Mouse deficient in the p50 subunit of NF-κB: a model to study the role of NF-κB in 
PCBs-induced carcinogenic process 
Although p65 knockout mice die during embryogenesis (Beg et al. 1995), p50 -/- 
knockout mice are viable (Sha et al. 1995). Based on the study by DeAngelis et al., there 
is no noticeable difference in liver regeneration after a PH, or in liver repairing functions 
(hepatocyte DNA synthesis, mitosis and serum enzyme levels) after treatment with CCl4 
between the p50-/- mice and wild type mice (DeAngelis et al. 2001). In this study, a 
decrease in the protein and mRNA levels of IκBα and an increase in the protein level of 
p65 subunit were observed in the p50-/- livers, which could provide a compensation for 
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the loss of p50. The known differences between livers of p50-/- mice and wild type mice 
are: the p50-/- livers showed more apoptosis than livers of wild type mice after treatment 
with Fas antibody, and the levels of interleukin-6 (IL-6) were reduced in p50-/- livers but 
still adequate to support liver regeneration. Studies in our laboratory have shown that 
peroxisome proliferator ciprofibrate increased hepatocyte proliferation in both wild type 
mice and p50-/- mice, but the increase in p50-/- mice was less than that in the wild type 
mice (Tharappel 2001). In addition, p50-/- livers showed more apoptosis than the livers 
of wild type mice, apoptosis was reduced in p50-/- mice by treatment with ciprofibrate 
but was still higher than that in wild type mice. Thus, the p50-/- mice provide us a useful 
model to study the role of p65/p50 dimer (NF-κB) in the changes of cell proliferation and 
cell apoptotic death in response to treatment with PCBs. 
 
3. Rationale, Hypothesis and Specific Aims: 
A. Study Rationale and Hypothesis: 
In light of the fact that PCBs have been shown to cause oxidative stress, and the 
fact that other tumor promoters such as phenobarbital and peroxisome proliferators 
induce activation of NF-κB, the major focus of the present study is to test the hypothesis 
that specific PCB congeners can activate NF-κB, which, in turn, can cause an increase in 
cell proliferation and/or inhibition of cellular apoptotic cascade. Also, the levels of 
dietary antioxidants will affect PCBs-induced NF-κB activation, which will cause an 
effect on the tumor promoting activities of specific PCB congeners.   
 
B. Specific Aims: 
The generation of reactive oxygen species has been a proposed mechanism by 
which some xenobiotics produce cancer. Studies have indicated that hepatic tumor 
promotion is an imbalance between cell proliferation and apoptosis. The transcription 
factor NF-κB is stimulated by oxidative stress and can lead to cell proliferation. We 
hypothesize that oxidative stress plays an important role in PCBs-induced tumor 
promotion, through the activation of NF-κB. To test this hypothesis, we proposed the 
following specific aims: 
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Specific Aim 1: 
Determine the effects of selected PCB congeners on the hepatic NF-κB activation 
and cell proliferation. 
 The data in chapter 2 shows that a single dose of non-coplanar PCB congener 
PCB-153 caused hepatic NF-κB activation and cell proliferation in rat liver, while PCB-
77, a coplanar PCB congener, showed no effects on NF-κB activation or cell 
proliferation.  
 
Specific Aim 2:  
 Determine the roles of NF-κB in PCBs-altered hepatocyte proliferation and 
apoptosis. A p50 knockout mouse model was used in chapter 3 to examine effect of the 
absence of p50 subunit on the cell proliferation and apoptosis in the liver. The data in 
chapter 3 show an important role of NF-κB in the regulation of cell proliferation and 
apoptosis. A single dose of PCB-153 caused NF-κB activation and an increase in cell 
proliferation in wild type liver, but not in p50-/- livers. Cell proliferation was increased in 
p50-/- livers by multiple doses of PCB-153 after a longer exposure (21 days), but it was 
still lower than that in the wild type livers. Comparison of the mRNA levels of cyclin A2, 
B1, B2, C, D1 and D2 failed to show any difference between p50-/- and wild type livers, 
but I observed a decrease in the protein level of cyclin D1 in the p50-/- livers, as 
compared to the wild type livers. In addition, p50-/- livers showed a higher incidence of 
spontaneous apoptosis than wild type livers, and PCB-153 inhibited apoptosis in the p50-
/- livers.  
 
Specific Aim 3: 
 To determine the effect of dietary vitamin E (α-tocopherol acetate) on PCBs-
induced hepatic focal lesion growth and cell proliferation during the promotion stage, and 
the effect of dietary vitamin E on PCBs-induced hepatic NF-κB activation. Data from 
chapter 4 show that both PCB-77 and PCB-153 induced the number and volume of 
placental glutathione S-transferase (PGST)-positive foci after diethylnitrosamine (DEN) 
initiation. Both vitamin E deficiency (10 ppm) and supplementation (250 ppm) caused an 
insignificant increase in the number and volume of PGST-positive foci compared to rats 
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received sufficient vitamin E (50 ppm). For hepatocyte proliferation, PCB-77 
significantly increased cell proliferation in PGST-positive and –negative hepatocytes in 
low (10 ppm) and medium (50 ppm) vitamin E groups, the high level of dietary vitamin E 
(250 ppm) inhibited cell proliferation in both normal and PGST-positive hepatocytes, 
with more pronounced effect on normal hepatocytes. It was also observed that PCB-77 
caused hepatic NF-κB activation, and the high level of vitamin E showed an insignificant 
inhibitory effect on NF-κB activation by PCB-77.  
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Chapter 2. Increased hepatic NF-κB DNA binding activity and cell 
proliferation by a single dose of polychlorinated biphenyls (PCBs) in 
rats 
 
Introduction 
PCBs cause several of toxic effects in liver, including liver hypertrophy, 
neoplastic nodules, and hepatocellular carcinoma (Safe 1994). PCBs have been shown to 
enhance cancer formation in animals after initiated with a genotoxic reagent. Thus, PCBs 
and related compounds induce cancer as tumor promoters (Glauert 2001; Safe 1994; 
Silberhorn et al. 1990).  The mechanisms of the promoting activity of PCBs, however, 
have not been determined. Other hepatic tumor promoters, such as phenobarbital and 
peroxisome proliferators, act by suppressing apoptosis and/or increasing cell proliferation 
(Bayly et al. 1994; Cunningham 1996; Gill et al. 1998; Roberts et al. 1995; Shane et al. 
2000). These changes are brought about by changes in the expression of genes related to 
cell proliferation or apoptosis. Another theory of tumor promotion is by oxidative stress, 
reactive oxygen species (ROS) in the form of superoxide or hydrogen peroxide can be 
released as a by-product from cytochrome P-450 and could contribute to lipid 
peroxidation (Goeptar et al. 1995). Other sources of oxidative stress may include other 
induced enzymes, the repression of antioxidants or antioxidant enzyme. Formations of 
ROS during PCBs exposure and metabolism have been detected in cell-free systems 
(McLean et al. 1996; Oakley et al. 1996), in cell cultures (Slim et al. 2000), and in 
laboratory animals (Dogra et al. 1988; Kamohara et al. 1984; Pelissier et al. 1990; Pereg 
et al. 2002; Saito 1990; Twaroski et al. 2001a; Twaroski et al. 2001b). Biomarkers of 
PCBs-induced oxidative stress include lipid peroxidation (Kamohara et al. 1984; Pelissier 
et al. 1990; Peltola et al. 1994; Saito 1990), DNA-single strand break (Srinivasan et al. 
2001), and decrease in antioxidant defense (Peltola et al. 1994; Twaroski et al. 2001b).    
Recently, hepatic tumor promoters such as peroxisome proliferators and 
phenobarbital have been found to activate transcription factors (e.g. NF-κB) that regulate 
the expression of cell proliferation- and apoptosis-related genes (Li et al. 2000; Li et al. 
1996a; Li et al. 1996b; Nilakantan et al. 1998).  The activation of NF-κB and AP-1 has 
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been found to be mediated by active oxygen (Abate et al. 1990; Amstad et al. 1992; 
Schreck et al. 1992). NF-κB has been considered as a sensitive biomarker of oxidative 
stress (Li & Karin 1999). 
NF-κB is present in cytoplasm as an inducible heterodimer and usually consists of 
two subunits, a 50-kDa (p50) and a 65-kDa (p65) polypeptide that are complexed to an 
inhibitory subunit (IκB). Upon stimulation, IκB is phosphorylated, ubiquinated and 
degraded; NF-κB then can translocate into the nucleus, bind to the κB-binding site in 
promoter region of target genes and alter their expression. These target genes include 
those that are involved in cell proliferation, including cyclin D1, and others that are anti-
apoptotic, such as cIAPs and Bcl-2/Bcl-xL (Guttridge et al. 1999; Hinz et al. 1999) (Lee 
et al. 1999; Tamatani et al. 1999; Wang et al. 1999; Wang et al. 1998). Knockout studies 
revealed that the p65 subunit of NF-κB is essential for cell to survive the TNF-α induced 
apoptosis, because deficiency in p65 is lethal (Beg et al. 1995).    
The main goal in this study was to explore mechanisms by which PCBs may exert 
their tumor-promoting activities.  We therefore examined the effect of PCBs on the 
induction of oxidative stress in the form of activation of the transcription factors NF-κB 
and AP-1, and the effect of PCBs on cell proliferation. The PCBs used in this study were 
3,3’,4,4’–tetrachlorobiphenyl (PCB-77) and 2,2’,4,4’,5,5’-hexachlorobiphenyl (PCB-
153); these two congeners were used because of their different chemical structures and 
abilities to induce different cytochrome P-450s (Safe 1994) (Tharappel et al. 2002).   
 
Materials and Methods 
Materials: 3,3’,4,4’–tetrachlorobiphenyl (PCB-77) and 2,2’,4,4’,5,5’-hexachlorobiphenyl 
(PCB-153) were synthesized and characterized as described previously (Schramm et al. 
1985).  Vitamin E stripped corn oil was obtained from Acros Organics (Morris Plains, 
NJ). Alzet osmotic pumps (model 2ML1) were obtained from Alza Scientific Products, 
Palo Alto, CA. The anti 5-bromo-2’-deoxyuridine (BrdU) antibody was purchased from 
Becton-Dickinson (San Jose, CA). The Antigen Retrieval Citra solution was purchased 
from BioGenex (San Ramon, CA). All other chemicals were obtained from Sigma 
Chemical Co. (St. Louis, MO).  
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Experimental design and animal treatment: Male Sprague-Dawley rats weighing 200 
grams were obtained from Harlan Sprague Dawley (Indianapolis, IN) and housed three 
rats per cage in a temperature and light-controlled room. The rats were allowed to 
acclimatize for one week before starting the experiment. In the first study, the rats were 
injected intraperitoneally (i.p.) with corn oil (10 ml/kg), PCB-153 (30 or 150 µmol/kg), 
PCB-77 (30 or 150 µmol/kg), or both PCBs (30 µmol/kg each) dissolved in corn oil.  
Rats (3 per group) were killed 2, 6, or 24 hours, or 2, 6 or 10 days after the PCB 
injection. For all but the 10-day time point, rats were injected subcutaneously (s.c.) with 
5-bromodeoxyuridine (BrdU, 100 mg/kg) two hours before euthanasia.  For the 10-day 
time point, rats were implanted with Alzet osmotic pumps containing BrdU (20 mg/ml, 
10 µl/hr) 48 hours before euthanasia. In the second study, rats were injected i.p. with corn 
oil, PCB-77 (150 or 300 µmol/kg), PCB-153 (150 or 300 µmol/kg), or both PCBs (150 
µmol/kg each). The rats (5 per group) were euthanized 2 or 6 days after the PCB 
injection; two hours before euthanasia all rats were injected s.c. with 5-
bromodeoxyuridine (BrdU, 100 mg/kg).  In both studies, liver pieces were removed and 
fixed in 10% formalin; paraffin sections were then stained with hematoxylin and eosin 
for histopathological analysis or immunohistochemically stained for BrdU for the 
analysis of DNA synthesis.  The remainder of the liver was frozen in liquid nitrogen. 
 
BrdU immunohistochemical staining:   
Principle: BrdU is a synthetic analog of thymidine and can be incorporated into the DNA 
during replication (S phase). Immnuohistochemical techniques using a monoclonal 
antibody specific against BrdU allow for easy detection of BrdU incorporated nuclei, 
which indicates the relative rate of cell proliferation.  
Reagents: 
1. Hemo-De (Scientific Safety Solvent 15-182-507A) 
2. PBS (phosphate buffered saline), pH 7.4 
For 4 liters: 
1.05 g sodium phosphate (monobasic)  
4.51 g sodium phosphate (dibasic) 
32 g sodium chloride (Sigma Chemical Co. S3014) 
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3. 95% Ethanol  
4. H2O2 solution (make fresh) 
180 ml methanol + 20 ml 30% H2O2 (Sigma Chemical Co. H0904) 
5. 1 x Antigen Retrieval Citra 
10 x Antigen Retrieval Citra (BioGenex HK086-5K) diluted 10 time with distilled 
water before use. 
6. 10 x Automation Buffer (Biomedia Corp. M30) 
7. Diluted normal horse serum  
3 drops of normal horse serum (Vector Laboratories Peroxidase Kit PK-6102) 
10 ml 1 x automation buffer 
8. Blocking Kit (Vector Laboratories SP-2001) 
Contains Avidin solution and Biotin solution 
9. Diluted primary antibody (anti-BrdU) 
25 µl of antibody (Becton Dickinson 347580) 
975 µl 1 x automation buffer 
10. Diluted biotinylated anti-mouse IgG 
1 drop of biotinylated anti-mouse IgG (Vector Laboratories Peroxidase Kit PK-6102) 
3 drops of diluted normal horse serum 
10 ml 1 x automation buffer 
11. ABC solution  
3 drops of A (Vector Laboratories Peroxidase Kit PK-6102) 
3 drops of B (Vector Laboratories Peroxidase Kit PK-6102) 
10 ml 1 x automation buffer 
allow solution to stand at room temperature for 20-30 minutes before use 
12. DAB staining solution (make fresh)  
1 drop of buffer (Vector Laboratories Peroxidase Substrate Kit SK-4100) 
2 drops of DAB 
1 drop of H2O2 solution  
2.5 ml distilled water 
13. 1% acid alcohol 
140 ml absolute ethanol 
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60 ml distilled water 
2 ml HCl (Sigma Chemical Co. H7020) 
14. Ammonium hydroxide solution 
200 ml distilled water 
10-15 drops of ammonium hydroxide (J. T. Baker Chemical Co. 9721) 
15. Harris hematoxylin solution (Sigma Chemical Co. HHS-32) 
Procedures: 
1. The slides were dried in 60 °C oven for 30 minutes.   
2. The slides were de-paraffined in Hemo De for a total of three changes (15 minutes 1st 
and 5 minutes for 2nd and 3rd change). 
3. The slides were placed in 100% ethanol for 2 changes (5 minutes each change). 
4. The slides were dipped in 95% ethanol for 5 minutes. 
5. The slides received 3 rinses with tap water. 
6. The slides were placed in the methanol:hydrogen peroxide solution (made fresh) for 
10 minutes. 
7. The slides received 3 rinses with tap water. 
8. While being submerged in 1x antigen retrieval citra, the slides were heated in a 
microwave for 15 minutes in 5-minute intervals. Caution was taken in making sure 
the sections were always covered with solution. 
9. The slides were cooled in the citra for 20 minutes. 
10. The slides were rinsed with tap water 3 times. 
11. Diluted Normal Horse Serum was added to the slides for 10 minutes at room 
temperature (3 drops/slide). 
12. The horse serum was drained and the Avidin Block (undiluted) was added to the 
slides for 15 minutes (2 drops/slide). 
13. The slides were dipped briefly in PBS and Biotin Block was added to the slides for 15 
minutes at room temperature (2 drops/slide). 
14. The slides were drained (not rinsed) and the diluted anti-BrdU primary 
antibody was added to the slides for 30 minutes at 37 °C (100 µl/slide  
using a 1:40 dilution of BrdU). 
15. The slides were rinsed 2 times with PBS (5 minutes each). 
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16. Two drops of diluted Biotinylated Anti-mouse IgG were added to each slide for 15  
minutes at 37 °C. 
17. The slides were rinsed twice with PBS (5 minutes each). 
18. Two drops of the ABC solution was applied to each slide for 15 minutes at 37 °C (3 
drops A, 3 drops B, 10 ml 1x Automation Buffer – let stand 20-30 minutes before 
use). 
19. The slides were rinsed with PBS twice (5 minutes each). 
20. The DAB staining solution was added to each slide for 2-10 minutes at room 
temperature (enough to completely cover the sectioned tissue). This solution was 
made fresh, and each slide was monitored using a microscope to determine when 
staining was complete.  
21. The slides were gently rinsed in tap water. 
22. The slides were dipped in Hematoxylin for 1 minute.  This solution was filtered daily 
with No. 1 Whatman Filter Paper. 
23. The slides were dipped in tap water. 
24. The slides were quickly dipped in 1% acid alcohol solution. 
25. The slides were dipped several times in tap water. 
26. Three dips were made in the ammonium hydroxide solution.  
27. The slides were gently rinsed in running tap water for 5 minutes. 
28. In order to dehydrate the slides, they were dipped 10 times in 95% ethanol, 100% 
Ethanol (3 jars) and Hemo-De (3 jars) for a total of 70 dips. 
29. The slides were mounted with Permount medium (Fisher Scientific Co. SP15-500) 
and covered with cover slips (Clay Adams 3322).  The slides were allowed to air dry 
before counting nuclei. 
Counting: 
1. Cells that had incorporated BrdU were easily identified with brown nuclei.  At least 
3000 hepatocellular nuclei were counted randomly per slide.  
2. Labeling index (%) =     number of labeled nuclei    x  100 
total number of nuclei counted    
 
Isolation of nuclear protein: 
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Reagents: 
1. 5 M NaCl  
146.1 g NaCl (Sigma Chemical Co. S3014) 
Brought final volume to 500 ml with autoclaved H2O 
2. 1 M Hepes-KOH, pH 7.9 
23.8 g Hepes (Sigma Chemical Co. H0891) 
Added 80 ml autoclaved water and brought pH to 7.9 with KOH pellets.  Final 
volume was 100 ml 
3. 0.5 M EDTA, pH 8.0 
18.61 g EDTA (Sigma Chemical Co. E5134) 
Add 80 ml autoclaved water and bring pH to 8.0. 
Brought final volume to 100 ml 
4. 1 M MgCl2 
20.33 g MgCl2 (Sigma Chemical Co. M2670) 
Brought final volume to 100 ml with autoclaved H2O 
5. IGEPAL CA-630 (Sigma Chemical Co. I3021) 
6. Glycerol (Sigma Chemical Co. G5516) 
7. 0.1 M Phenylmethylsulfonyl fluoride (PMSF)  
0.0174 g PMSF (Boehringer Mannheim 837 091)    
1 ml 100% ethanol and keep in freezer.  
8. 0.1 M Dithiothreitol (DTT)   
     0.0154 g of DTT (Bio-Rad 161-0611) 
     1 ml autoclaved water 
9. 0.1 M Benzamidine 
0.0156 g Benzamidine (Sigma Chemical Co. B6506)   
1 ml autoclaved water 
10. 1.0 mg/ml Aprotinin 
1 mg aprotinin (Sigma Chemical Co. A1153)   
1 ml autoclaved water (aliquot and stored in freezer) 
11. 1.0 mg/ml Leupeptin 
1 mg leupeptin (Sigma Chemical Co. L2884) 
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1 ml autoclaved water (aliquot and stored in freezer) 
12. 1.0 mg/ml Pepstatin A  
1 mg pepstatin A (Sigma Chemical Co. P4265) 
Dissolved in the 100 µl DMSO (Sigma Chemical Co. D8779) and brought the volume 
to 1 ml with autoclaved water (aliquot and stored in freezer) 
Buffers: 
1. Buffer A:  about 5 ml for 0.3 g tissue 
Stock   Amount added Final Conc. 
IGEPAL CA-630 0.18 ml 0.6% 
5M NaCl 0.9 ml 150 mM 
1 M Hepes, pH 7.9 0.3 ml 10 mM 
0.5 M EDTA 60 µl 1 mM 
0.1 M PMSF (added last) 150 µl 0.5 mM 
Sterilized water 28.41 ml  
TOTAL 30 ml  
 
2. Buffer C:  120 µl/0.3 g tissue 
Stock         Amount added             Final Conc. 
100% Glycerol   0.25 ml    25% Glycerol 
1 M Hepes, KOH, pH 7.9  20 µl     20 mM  
5 M NaCl    84 µl     420 mM 
1 M MgCl2    1.2 µl     1.2 mM 
0.05 M EDTA                4 µl     0.2 mM 
0.1 M PMSF    5 µl     0.5 mM 
0.1 M DTT    5 µl     0.5 mM 
0.1 M Benzamidine   20 µl     2 mM  
1 mg/ml Aprotinin   5 µl     5 µg/ml 
1 mg/ml Leupeptin   5 µl     5 µg/ml 
1 mg/ml Pepstatin   5 µl     5 µg/ml 
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Sterilized water                      595.8 µl    
TOTAL                                              1000 µl 
 
Procedure: 
1. Buffer A was prepared and kept on ice. 
2. The liver was removed from freezer and kept on dry ice.  The tissue was broken into 
smaller pieces.   
3. Approximately 0.3 g of tissue and 5 ml of cold Buffer A were added to a 15-ml 
Dounce tissue homogenizer.  Eight strokes were made and the homogenate was 
transferred to a 15 ml tube.   
4. The homogenate was centrifuged at 270 x g for 30 seconds to rid unbroken tissue 
(1000 rpm for Mistral 3000i centrifuge).   
5. The supernatant was transferred to a 15 ml tube and kept on ice for at least 5 minutes.     
6. The supernatant was centrifuged at 2980 x g for 20 minutes (3600 rpm for Mistral 
3000i centrifuge). 
7. During the 20 minute spin, buffer C was prepared. 
8. The supernatant was discarded.  The walls of the tube were cleaned with a Kim-wipe 
or cotton swab in other to rid the fat that clings to the walls.   
9. The pellet was resuspended in 1 ml of buffer A and transferred to a microcentrifuge 
tube. 
10. The resuspended pellet was centrifuged at 7,000 rpm for 3 minutes.    
11. The supernatant was discarded, and the pellet was resuspended with buffer C (120 µl  
for 0.3 g of liver tissue).  The pellet was incubated with buffer C on ice for 1 hour for 
high-salt extraction.    
12. The tubes were spun at maximum speed for 10 minutes in microcentrifuge. The 
supernatant was the nuclear extract. 
13.  The nuclear extract was aliquoted and stored at –80 °C.  One aliquot was diluted in 
PBS to measure the protein concentration using the BCA method (Pierce). Care was 
taken to avoid freeze-thawing of the nuclear extracts.   
 
Protein assay: 
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Principle: Cu+2 is reduced to Cu+1 by proteins (sample) in an alkaline environment 
(Reagent A).  The chelation of two molecules of bicinchoninic acid BCA (in Reagent B) 
with one Cu+1 forms a complex, which exhibits an absorbance at 562 nm.   
Reagents:   
1. Reagent A (Pierce Chemical Company 23223) 
2. Reagent B (Pierce Chemical Company 23224) 
3. Standards - Bovine gamma globulin (Bio-Rad 500-0005) was dissolved in PBS to 1.4 
mg/ml, aliquoted, and stored at -20°C.  One aliquot of the 1.4 mg/ml stock solution 
was used to make the working standard concentrations: 0.2, 0.4, 0.6, 0.8, and 1.0 
mg/ml. 
Procedure: 
1. 200 µl of mixed reagent (1 part Reagent A and 50 parts Reagent B) was added to each 
well of a 96-well plate.     
2. 10 µl of each diluted sample and 10 µl of each standard was added to each well in 
duplicate.  Note:  all dilutions were made in phosphate buffered saline (PBS). 
3. The 96-well plate was incubated for 30 minutes at 37°C. 
4. The plate was cooled to room temperature and read at 562 nm with a Bio-Tek plate 
reader (Model 312, Bio-Tek Instruments, Inc.).  Using the KinetiCalc software (Bio-
Tek Instruments, Inc.), the concentration of protein (mg/ml) was calculated based on 
the standard curve. 
 
Electrophoretic mobility shift assay (EMSA): 
 Reagents: 
1. [r-32P] ATP - 6000Ci/mmol at 10mCi/ml (NEN Life Science BLU/NEG/002Z) 
2. 0.5 M EDTA, pH 8.0  
3. TE buffer (10 mM Tris-HCl, pH 7.5 and 1 mM EDTA) 
4. T4 Polynucleotide Kinase (New England Biolabs M0201S) 
5. 30% Acrylamide (29:1) (Bio-Rad Laboratories 161-0156) 
6. 10% Ammonium Persulfate (APS) 
0.5 g APS (Sigma Chemical Co. A9164) 
5 ml autoclaved water 
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7. TEMED (Sigma Chemical Co. T7024) 
8. Nonidet P-40 (Sigma Chemical Co. P4504) 
9. 1 M Hepes-KOH, pH 7.9 
10. 1 M KCl 
11.  0.1 M Dithiothreitol (DTT, Bio-Rad 161-0611) 
12. 100% Glycerol (Sigma Chemical Co. G5516) 
13. NF-κB consensus oligonucleotide (Promega E329A ) 
14.  AP-1 consensus oligonucleotide (Santa Cruz sc-2501) 
15. 1 mg/ml Poly (dI-dC)·(dI-dC) (Amersham Pharmacia Biotech 277880)  
Dissolved in TE (10 mM Tris and 1 mM EDTA, pH 7.5) 
16. 10x TBE  
108 g Tris base (Boehringer Mannheim 1814 273) 
54 g Boric acid (Gibco 15583-024) 
40 ml 0.5 M EDTA, pH 8.0 (bring to 1 liter with water) 
Procedure: 
1. Radiolabel NF-κB and AP-1 probe 
a. Add below into an microcentrifuge tube  
Nuclease-free water       5 µl 
NF-κB or AP-1 consensus oligonucleotide (1.75 pmol/µl) 2 µl 
T4 Polynucleotide Kinase 10x Buffer   1 µl 
[r-32P] ATP       1 µl 
T4 Polynucleotide Kinase (10 U/µl)    1 µl    
a. The reactions were incubated at 37 °C for 20 minutes. 
b. Each reaction was stopped with 1 µl of 0.5 M EDTA with phenol red. 
2. Purification of labeled probe 
The labeled oligonucleotide was separated from unincorporated nucleotides by 
passing the reactions through a Bio-gel column (Bio-Rad Laboratories 151-0440).  
The components of each reaction were added to the center of the column and washed 
with TE buffer.  The radioactive peak was collected, and 1 µl was counted using a 
liquid scintillation counter.  The average cpm for 1 µl was 50,000.  The radiolabeled 
probe was stored at –20 °C until use.     
3. Electrophoresis Mobility Shift Assay (EMSA) 
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a. Made 5x binding buffer (according to Promega): 
Stock For 5 ml 5x binding 
buffer (stock) 
1x binding buffer (final 
concentration in reaction) 
1 M Hepes, pH 7.9 
 
250 µl 50 mM  10 mM  
1 M KCl 1.25 ml 250 mM KCl 
 
50 mM KCl 
0.5 M EDTA 
 
10 µl 1 mM EDTA 
 
0.2 mM EDTA 
0.1 M DTT 625 µl 12.5 mM DTT 
 
2.5 mM DTT 
100% glycerol 2.5 ml 50% glycerol 
 
10% glycerol 
NP-40 12.5 µl 0.25% NP-40 
 
0.05% NP-40  
Autoclaved H2O 352.5 µl   
  
b. A 7% polyacrylamide gel was cast 
                                                             30 ml 
Water                          21.19 ml 
30% acrylamide/bis(29:1)      7 ml 
TBE (10x)         1.5 ml 
10% APS        0.3 ml 
TEMED         15 µl 
c. The gel was allowed to solidify for at least 45 minutes.  
d. The reaction was carried out as follows: 
Nuclear extracts           5 µg 
5x binding buffer         4 µl  
Poly (dI-dC)              0.2 µg  
Radiolabeled probe      2 µl (100,000 cpm) 
Autoclaved water          brought total volume to 20 µl 
 
All contents except for the radiolabeled probe were pre-incubated on ice for 5 
minutes.  The radiolabeled NF-κB or AP-1 probe was added to the reaction and 
incubated for 15 minutes at room temperature. 
e. The comb was removed and the wells were rinsed with 0.5 X TBE buffer using a 
needle and syringe.  The 20 µl reaction mixture was added to each well of the 7% 
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polyacrylamide gel and electrophoresed for 2 hours at 180 volts using 0.5 x TBE 
as the running buffer.  A positive control was included with each gel (HeLa cell 
extract, Santa Cruz).  
f. In order to confirm binding specificity of NF-κB, 1 µg of antibody raised against 
p50 or p65 were added to the reaction before adding the NF-κB probe (during the 
10 minute pre-incubation).       
After removing the gel from the running apparatus, the gel was attached to filter paper 
and covered with plastic wrap.   The gel was dried under vacuum and exposed overnight 
at –80 °C to Kodak XOMAT-AR film. The radioactivity was counted with a 
radioanalytic imaging system (Ambis, San Diego, CA). 
 
Statistical analysis: 
 Results were first analyzed by one-way analysis of variance and Dunnett’s post 
hoc test. The results were reported as means + standard error of mean (SEM). 
 
Results 
 In this study, we have examined the hypothesis that specific PCB congeners could 
activate oxidative stress-related transcription factors and induce cell proliferation.  In the 
first study, rats received corn oil, PCB-77 (30 or 150 µmol/kg), PCB-153 (30 or 150 
µmol/kg), or combination of the two PCBs (30 µmol/kg for each PCB). Liver tissue was 
collected at 2, 6, 24 hours or 2, 6 and 10 days after the injection. The liver/body weight 
ratio was not significantly different among any of those groups before day 6 (Table 2.1). 
The high dose of PCB-77 significantly increased the liver to body weight ratio at day 6, 
and by day 10 the ratio was significantly increased by both doses of PCB-77, the high 
dose of PCB-153 and the combination of two PCBs. The DNA binding activities of the 
transcription factors NF-κB and AP-1 were examined by EMSA, and were not 
significantly changed by any of the PCBs at any time points, although there was a slight 
increase in the DNA binding activities of NF-κB by high dose of PCB-153 and the 
combination of both PCBs after 2 days (Tables 2.2 and 2.3). The specificity of the DNA 
binding of two factors was determined by supershift using nuclear extract from high-dose 
PCB-153 group and antibodies against NF-κB subunits (p50 and p65) or AP-1 subunits 
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(c-Fos and c-Jun). The presence of either the anti-p65 or anti-p50 antibody resulted in a 
supershifted complex, indicating that both p50 and p65 subunits were present in the NF-
κB protein-DNA complex (Figure 2.1). Antibody specific to c-Fos led to a supershifted 
complex and the anti-c-Jun antibody caused a 30% reduction in the intensity of the AP-1 
protein-DNA complex (Figure 2.2), indicating the presence of both c-Fos and c-Jun in 
the AP-1 protein-DNA complex. 
To measure the rate of cell proliferation, we quantified the labeling index after 
rats were administered BrdU. The labeling indexes of the PCB-treated groups were not 
significantly different from the control group at any of the six time points tested (Table 
2.4). 
In our initial study, there was a slight increase in the DNA binding activity of NF-
κB and in the labeling index in rats treated with PCB-153 and the combination of two 
PCBs at day 2, but these differences were not statistically significant. Based on these 
observations, we administered higher doses of PCBs:  rats received corn oil, PCB-77 
(150 or 300 µmol/kg), PCB-153 (150 or 300 µmol/kg), or both PCBs (150 µmol/kg 
each), and rats were euthanized after 2 or 6 days. The liver to body weight ratio was 
increased in both PCB-77 groups and the group receiving both PCBs at day 6, but PCB-
153 did not have a significant effect on the liver weight (Table 2.5).  At day 2, there was 
no difference in the liver to body weight ratio between any PCB group and the control 
group. EMSAs were used to determine the DNA binding activity of NF-κB and AP-1. 
PCB-153 treatment increased NF-κB binding activity at day 2, but not at day 6; the other 
treatments had no effect (Figures 2.3 and 2.4). The DNA binding activity of AP-1 was 
not increased by any PCB at either time point (Figures 2.5 and 2.6).           
The rate of cell proliferation in the second study, as measured by quantitation of 
the BrdU labeling index, was increased in the high-dose (300 µmol/kg) PCB-153 group 
and the group receiving both PCBs compared to the corn oil-treated controls at day 2 
(Figure 2.7). The labeling index was not significantly different in rats treated with either 
dose of PCB-77, or the low dose of PCB-153, compared to corn oil-treated controls. At 
day 6, there were no significant differences in the BrdU labeling index between any PCB 
group and the control group. 
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Table 2.1. Effect of PCBs on liver weight 
________________________________________________________________________ 
 
                                                         Liver weight (% of body weight) 
______________________________________________________ 
     
Treatment Dose       2 h           6 h            24 h         2 days  6 days      10 days 
         (µmol/kg) 
________________________________________________________________________ 
 
Corn Oil  4.85 + 0.10   4.25 + 0.10   4.83 + 0.13   4.82 + 0.14   4.60 + 0.19   4.40 + 0.05 
   
PCB-77 30 4.82 + 0.04   4.44 + 0.17   4.98 + 0.06   5.10 + 0.15   4.93 + 0.02   5.07 + 0.15* 
    
PCB-77 150 4.56 + 0.08   4.74 + 0.01   5.24 + 0.10   5.25 + 0.14   5.52 + 0.09*  5.59 + 0.07*    
   
PCB-153 30 4.82 + 0.13   4.44 + 0.16   5.01 + 0.19   4.77 + 0.12   5.01 + 0.02   4.78 + 0.03 
 
PCB-153 150 4.73 + 0.03   4.24 + 0.09   4.93 + 0.11   4.71 + 0.03   5.01 + 0.23   5.13 + 0.20*  
 
Both PCBs    30+30 4.96 + 0.05   4.76 + 0.14   5.13 + 0.18   5.02 + 0.03   4.95 + 0.17   5.38 + 0.17* 
________________________________________________________________________ 
 
Each value is the mean + SEM.  PCB-77 or PCB-153 (30, 150 µmol/kg) or both PCBs 
were given in corn oil as a single i.p. dose.  Control animals received the vehicle. Each 
group contained 3 animals. *Values are significantly different from controls (p < 0.05). 
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Figure 2.1. Determination of NF-κB specific binding. Antibodies specific for NF-κB 
subunits (p50 and p65) were added to the reaction containing a radiolabeled NF-κB 
oligonucleotide and liver nuclear extracts from high level PCB-153 group.   
 
N.E.             +    +    +   +
Anti-p50 - +     - +
Anti-p65 - - +    +
NF-κB 
}Supershift  
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Figure 2.2. Determination of AP-1 specific binding. Antibodies specific for AP-1 
subunits (c-Fos and c-Jun) were added to the reaction containing a radiolabeled AP-1 
oligonucleotide and liver nuclear extracts from high level PCB-153 group.   
 
N.E.                     +   +     +    +
Anti-c-Fos - +     - +
Anti-c-Jun - - +    +
AP-1 
Supershift 
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Table 2.2. Effect of PCBs on hepatic DNA binding activity of NF-κB 
________________________________________________________________________ 
 
                                                        Hepatic NF-κB Activity (% of control) 
______________________________________________________ 
     
Treatment Dose       2 h           6 h            24 h         2 days  6 days      10 days 
         (µmol/kg) 
________________________________________________________________________ 
 
Corn Oil     100 + 8    100 + 9       100 + 4       100 + 15      100 + 11      100 + 2 
   
PCB-77 30      92 + 2      63 + 8         96 + 21       84 + 09     1.81 + 36      132 + 19 
    
PCB-77 150    106 + 11     68 + 6       119 + 28    105 + 27      172 + 32      108 + 16 
   
PCB-153 30    122 + 21   100 + 24     102 + 21    124 + 29      118 + 22      108 + 17 
 
PCB-153 150      60 + 10     77 + 32      85 + 11     169 + 34      124 + 36      100 + 15  
 
Both PCBs    30+30      75 + 19    102 + 5      140 + 24     232 + 56     172 + 35      108 + 6 
________________________________________________________________________ 
 
Each value is the mean + SEM.  PCB-77 or PCB-153 (30, 150 µmol/kg) or both PCBs 
were given in corn oil as a single i.p. dose.  Control animals received the vehicle alone. 
Each group contained 3 animals. EMSAs were performed using a radiolabeled NF-κB 
oligonucleotide with rat liver nuclear extracts. NF-κB DNA binding activity was 
quantified by measurement of the net cpm of NF-κB band using a radioanalytic imaging 
system (Ambis Corp., San Diego, CA).   
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Table 2.3. Effect of PCBs on hepatic DNA binding activity of AP-1 
________________________________________________________________________ 
 
                                                          Hepatic AP-1 Activity (% of control) 
______________________________________________________ 
     
Treatment Dose          2h             6 h            24 h         2 days     6 days       10 days 
         (µmol/kg) 
________________________________________________________________________ 
 
Corn Oil       100 + 6         100 + 9         100 + 18        100 + 15       100 + 9         100 + 11 
   
PCB-77 30        86 + 9           73 + 8         108 + 11          95 + 9         121 + 26       112 + 6 
 
PCB-77 150      106 + 8         109 + 5         121 + 16         132 + 20         92 + 6          96 + 12 
   
PCB-153 30      105 + 15       105 + 24       102 + 11         114 + 24         88 + 21         94 + 6 
 
PCB-153 150        90 + 8           82 + 25       111 + 21         144 + 3           73 + 16       103 + 16 
 
Both PCBs    30+30      121 + 14       133 + 8         131 + 12         192 + 20       147 + 35       116 + 8 
________________________________________________________________________ 
 
Each value is the mean + SEM.  PCB-77 or PCB-153 (30, 150 µmol/kg) or both PCBs 
were given in corn oil as a single i.p. dose.  Control animals received the vehicle alone. 
Each group contained 3 animals. EMSAs were performed using a radiolabeled AP-1 
oligonucleotide with liver nuclear extracts from each rat. AP-1 DNA binding activity was 
quantified by measurement of the net cpm of AP-1 band using a radioanalytic imaging 
system (Ambis Corp. San Diego, CA).   
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Table 2.4. Effect of PCBs on hepatic cell proliferation 
________________________________________________________________________ 
 
                                                          BrdU index (100%) 
______________________________________________________ 
     
Treatment Dose       2 h           6 h            24 h         2 days  6 days      10 days 
         (µmol/kg) 
________________________________________________________________________ 
 
Corn Oil  0.93 + 0.31   0.81 + 0.14   1.15 + 0.35   0.87 + 0.28   1.04 + 0.26   1.08 + 0.20 
   
PCB-77 30 2.23 + 1.33   0.60 + 0.07   1.01 + 0.15   0.97 + 0.26   1.18 + 0.36   0.86 + 0.34 
    
PCB-77 150 0.68 + 0.16   0.55 + 0.11   1.02 + 0.25   0.67 + 0.05   0.80 + 0.18   1.14 + 0.38    
   
PCB-153 30 2.02 + 0.53   0.80 + 0.10   0.60 + 0.31   1.10 + 0.53   1.00 + 0.27   1.22 + 0.25 
 
PCB-153 150 1.09 + 0.04   0.66 + 0.08   0.81 + 0.27   1.62 + 0.43   0.71 + 0.24   1.41 + 0.26  
 
Both PCBs    30+30 1.39 + 1.17   0.63 + 0.01   0.91 + 0.26   2.09 + 0.35   0.76 + 0.07   0.85 + 0.36 
________________________________________________________________________ 
 
Each value is the mean + SEM.  PCB-77 or PCB-153 (30, 150 µmol/kg) or both PCBs 
were given in corn oil as a single i.p. dose.  Control animals received the vehicle alone. 
Each group contained 3 animals. Rats were administrated BrdU either by a 2-day infusion 
using Alzet osmotic pumps (10 days only) or by a s.c injection (all other time points). 
Tissue sections were immunohistochemically stained for BrdU and labeling indexes were 
determined.  
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Table 2.5. Effect of high dose of PCBs on liver weight 
________________________________________________________________________ 
 
                                                         Liver weight (% of body weight) 
______________________________________________________ 
     
Treatment Dose    2 days     6 days       
         (µmol/kg) 
________________________________________________________________________ 
 
Corn Oil    5.20 + 0.08     4.86 + 0.14 
   
PCB-77 150   5.50 + 0.10      5.90 + 0.27* 
    
PCB-77 300   5.60 + 0.13      5.84 + 0.25*    
   
PCB-153 150   5.18 + 0.15      5.19 + 0.15 
 
PCB-153 300   5.23 + 0.21      5.52 + 0.09  
 
Both PCBs    150+150    5.79 + 0.12      6.31 + 0.19* 
________________________________________________________________________ 
 
Each value is the mean + SEM.  PCB-77 or PCB-153 (150, 300 µmol/kg) or both PCBs 
were given in corn oil as a single i.p. dose.  Control animals received the vehicle alone. 
Each group contained 5 animals. *Values are significantly different from controls (p < 
0.05). 
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Figure 2.3. Effect of high dose of PCBs on the hepatic DNA binding activity of NF-κB. 
EMSAs were performed using a radiolabeled NF-κB oligonucleotide with control HeLa 
nuclear extract or liver nuclear extracts from individual rats. Lane 1, HeLa cell nuclear 
extract as a positive control; remaining lines, liver nuclear extracts from a single rat (5 
µg). F.P., free probe.  A. EMSA in 2-day study. B. EMSA in 6-day study. 
 45
 
A. 
   
 
B. 
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Figure 2.4. Relative radioactive counts of NF-κB bands from the EMSA data (Figure 
2.3). Quantitation of the specific NF-κB band was determined by subtracting background 
counts from the count in each NF-κB band. The radioactive counts of NF-κB from 
control groups were set as 100. *Values are significantly different from control group (p 
< 0.05). 
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Figure 2.5. Effect of high dose of PCBs on the hepatic DNA binding activity of AP-1. 
EMSA were performed using a radiolabeled AP-1 oligonucleotide with control HeLa 
nuclear extract or liver nuclear extracts from individual rats. Each line contains extracts 
from a single rat. Lane 1, HeLa cell nuclear extract as a positive control; remaining lanes, 
liver nuclear extracts from a single rat (5 µg). F.P., free probe. A. EMSA in 2-day study. 
B. EMSA in 6-day study. 
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A. 
  
 
B. 
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Figure 2.6. Effect of high dose of PCBs on the hepatic DNA binding activity of AP-1. 
Relative radioactive counts of AP-1 bands from the EMSA data (Figure 2.5). 
Quantitation of the specific AP-1 band was determined by subtracting background counts 
from the count in each AP-1 band. The radioactive counts of AP-1 bands from control 
groups were set as 100.  
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Figure 2.7. Effect of high dose of PCBs on cell proliferation. Rats were s.c. injected with 
BrdU 2 hours before euthanasia. Tissue sections were immunohistochemically stained for 
BrdU and labeling indexes were determined. Values of control groups are set as 100.  
Each group contained 5 animals. *Values are significantly different from control groups 
(p < 0.05). 
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Discussion 
 In this study, we have examined the hypothesis that single dose of specific PCB 
congeners could activate oxidative stress-sensitive transcription factors, namely NF-κB 
and AP-1. We found that PCB-153 at the highest dose tested transiently activated hepatic 
NF-κB in rats. This NF-κB activation by PCB-153 could be explained as results of 
oxidative stress caused by PCB-153, or the interactions between glucocorticoid receptor 
and PCB-153. PCB-153, a typical non-coplanar PCB congener, induces cytochrome P450 
2B family. Reactive oxygen species, such as superoxide and H2O2, can leak out of 
cytochrome P450 (Bondy & Naderi 1994; Goeptar et al. 1995), which would contribute 
to NF-κB activation. Another possible mechanism of NF-κB activation by PCB-153 is 
that PCB-153 or its metabolites could directly act on glucocorticoid receptor (GR), 
which, when activated, inhibits the activity of NF-κB (De Bosscher et al. 1997; De 
Bosscher et al. 2000; Heck et al. 1997), by direct or indirect mechanisms. 
Glucocorticoids induce transcription and protein synthesis of IκB (Auphan et al. 1995; 
Scheinman et al. 1995). Activated GR also antagonizes NF-κB activity through direct 
protein-protein interaction, and either prevents NF-κB binding to DNA (Adcock et al. 
1995; Steer et al. 2000) or associates with NF-κB bound to κB-binding site (De Bosscher 
et al. 2000; Nissen & Yamamoto 2000). Also, activated GR competes with NF-κB for 
nuclear coactivators (McKay & Cidlowski 2000; Sheppard et al. 1998). PCBs 
metabolites have been shown to act as competitive antagonist at the GR (Johansson et al. 
1998). In primary rat hepatocytes, PCB-153 and phenobarbital have been shown to 
suppress the expression of two sulfotransferase genes that are positively regulated by 
glucocorticoids (Runge-Morris 1998), which suggested a counteracting effect between 
PCB-153 and glucocorticoids although it is no clear if GR was involved.  
Our results indicated that PCB-77 alone, or PCB-77 and PCB-153 together, could 
not activate NF-κB. One mechanism by which coplanar PCBs could influence NF-κB 
activation is through their induction of the Aryl hydrocarbon (Ah) receptor. The activated 
Ah receptor has been found to bind to the p65 subunit of NF-κB (Tian et al. 1999), and 
this binding caused mutual function repression. TCDD has been found to activate NF-κB 
in wild-type mouse hepatoma Hepa-1 cells, but this increase in NF-κB DNA binding 
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activity was mainly due to an increase in p50/p50 complexes (Puga et al. 2000). Our lab 
has recently shown that NF-κB was activated after 4 injections of PCB-77 in an 
initiation-promotion study (Tharappel et al. 2002), which implied that this inhibition 
could be overcome by long-term treatment.  
Our study did not show any significant increase in hepatic DNA binding activity 
of AP-1, although there was a slightly increase by PCB-153 on day 2 (Figure 2.5). AP-1, 
as another oxidative stress-sensitive transcription factor, has been shown to be activated 
in rats with much higher dose of PCBs, in which 4 injections of PCB-3, PCB-28, or PCB-
153 (Oakley et al. 2001), 6 injections of PCB-77 or PCB-153 (Twaroski et al. 2001a), 
and 4 injections of PCB-77, PCB-153 or both PCBs (Tharappel et al. 2002) were given to 
rats. Recently, the IKK/NF-κB pathway has been shown to negatively modulate TNF-α-
mediated c-Jun N-terminal protein kinase (JNK) activation (De Smaele et al. 2001; 
Javelaud & Besancon 2001; Tang et al. 2001), and c-Jun/AP-1 activation was inhibited 
by NF-κB in rat hepatocyte cell line RALA255-10G (Liu et al. 2002). This negative 
crosstalk between NF-κB and JNK/c-Jun/AP-1 has been suggested to be mediated partly 
through the NF-κB-induced X-chromosome–linked inhibitor of apoptosis (XIAP) (Tang 
et al. 2001). Whether there is an interaction between PCBs-mediated NF-κB activation 
and c-Jun/AP-1 pathway is unclear, but studies with higher doses of PCBs showed that 
oxidative stress caused by higher dose of PCBs could induce the AP-1 activation. 
We have shown that high dose of PCB-153 and both PCBs induced cell 
proliferation (Figure 2.6). The commercial PCBs mixture Aroclor 1254 has been shown 
to induce hepatocyte proliferation in rats (Whysner & Wang 2001) and mice (Madra et 
al. 1995). The induction of cell proliferation correlated somewhat with increased NF-κB 
DNA binding activity, although this correlation was not absolute. This suggests that NF-
κB activation alone is not sufficient to cause increased cell proliferation after PCB 
exposure. 
Whether synergism exists between PCB congeners has attracted the attention of 
many investigators. We did not observe a synergistic effect between PCB-77 and PCB-
153 on NF-κB activation, which is in agreement with a previous study (Tharappel et al. 
2002). In contrast, cell proliferation was significantly induced by the combination of the 
two PCBs (150 µmol/kg each), while it was not significantly changed by either one of the 
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PCBs at the same concentration. Tharappel et al. observed no synergism between PCB-
77 and PCB-153 on cell proliferation and focal growth during tumor promotion 
(Tharappel et al. 2002). In other studies, antagonism has been shown between coplanar 
PCB congeners (77 or 126) and non-coplanar PCB congener (153) during tumor 
promotion (Berberian et al. 1995; Haag-Gronlund et al. 1998). How the PCB congeners 
exert synergistic effect on cell proliferation in early responses is not clear, but 
accumulating data suggested that depletion of hepatic retinol content by PCB-77 could 
contribute to the cell proliferation. Retinoic acid has been shown to inhibit DNA 
synthesis in primary rat hepatocytes (Ikeda & Fujiwara 1993). In rat liver, restoration of 
retinoic acid by dietary supplements inhibited ethanol-induced hepatocyte proliferation 
(Chung et al. 2001), which suggested that depletion of retinol content in liver contributes 
to cell proliferation. Both PCB-153 and PCB-77 lowered retinyl palmitate in liver, with a 
more pronounced effect by PCB-77, and the combination of these two PCBs produced a 
synergetic effect (Berberian et al. 1995). Durham and Brouwer have shown that hepatic 
retinol content was decreased (34% of control) 3 days after a single dose of PCB-77 
(Durham & Brouwer 1989). Thus, depletion of hepatic retinol by PCB-77 could 
contribute to the cell proliferation by PCB-153, and could be a possible mechanism of the 
synergism. 
 In the rats treated with highest dose of PCB-153, increased cell proliferation and 
NF-κB activation occurred in the same animals. Whether there is a relationship between 
NF-κB activation and cell proliferation following PCB-153 treatment need to be further 
investigated. The role of NF-κB in cell growth and tumorigenesis has been studied 
extensively due to the ability of NF-κB to modulate the transcription of genes whose 
products are involved in cell proliferation and the suppression of apoptotic cascades 
(Mayo & Baldwin 2000). Changes in those gene products are important for us to 
understand the possible connections between NF-κB activation and cell proliferative 
responses during tumor formation by PCBs.  
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Chapter 3. Effect of PCB-153 on hepatocyte proliferation and apoptosis 
in mice deficient in the p50 subunit of NF-κB 
 
Introduction 
 Polychlorinated biphenyls (PCBs) are a group of 209 synthetic aromatic isomers 
that are different in the position and number of chloride atoms in the biphenyl structure. 
Because of their physical properties, chemical stability, inflammability, and solubility in 
organic solvents, the use of PCBs was once widespread in industries until the late 1970s. 
Due to their stability and lipophilicity, they are widely distributed in the environment and 
bioaccumulate and bioconcentrate in the food chain, thus posing a health hazard to 
animals and humans (Safe et al. 1985; Safe 1994). Toxicity studies have shown that PCB 
mixtures can cause cancer in experimental animals, and that PCBs have tumor promoting 
activity (Glauert 2001; Silberhorn et al. 1990).  
 PCBs can be divided into two groups according to the different position of 
chlorination (Safe 1994; Silberhorn et al. 1990). Coplanar PCB congeners substituted in 
both para and at least two meta positions but not in any of the ortho positions may form a 
coplanar configuration similar to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and bind 
strongly to Ah receptor (AhR); the binding to Ah receptor induces expression of AhR-
regulated genes including cytochrome P450 1A1 and 1A2 (CYP 1A1, 1A2). On the other 
hand, PCB congeners with chlorine substitutes in two ortho-positions are non-coplanar, 
which have low affinity to Ah receptor but induce a battery of drug-metabolizing 
enzymes including cytochrome P450 2B1 and 2B2 (CYP2B1, CYP2B2), in a similar 
pattern as phenobarbital.    
PCBs promote the development of cancer in rodent liver when the animals 
pretreated with a genotoxic (initiating) carcinogen. The exact mechanisms by which 
PCBs exert their promoting activities are still unknown. Mechanisms including the 
inhibition of apoptosis and induction of cell proliferation in preneoplastic cells have been 
hypothesized. Recently, hepatic tumor promoters such as peroxisome proliferators and 
phenobarbital have been found to activate the transcription factor NF-κB, which regulates 
the expression of cell proliferation- and apoptosis-related genes.  
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In hepatocytes, the major form of NF-κB consists of two subunits, a 50-kDa (p50) 
and a 65-kDa (p65) polypeptide that are complexed to an inhibitory subunit (IκB) in the 
cytoplasm. Upon stimulation, IκB is phosphorylated, ubiquinated and degraded, allowing 
translocation of NF-κB into the nucleus. Among the NF-κB-regulated genes, cyclin D1 
controls the cell cycle checkpoint at G1/S phase (Guttridge et al. 1999; Hinz et al. 1999), 
and NF-κB is required for the initiation of cyclin D1 transcription and 
hyperphosphorylation of pRB, which lead cells to progress through G1 and entry into S 
phase (Biswas et al. 2000; Henry et al. 2000; Joyce et al. 1999; Kaltschmidt et al. 1999). 
NF-κB also regulates expression of certain anti-apoptotic genes, such as cIAPs (Wang et 
al. 1998) and Bcl-2/Bcl-xL (Lee et al. 1999; Tamatani et al. 1999; Wang et al. 1999). 
Knockout studies revealed that p65 subunit of NF-κB is essential for cell to survive the 
TNF-α induced apoptosis, because deficiency in p65 results in embryonic lethality (Beg 
et al. 1995). Inhibition of NF-κB by superrepressor IκBα  that has mutated 
phosphorylation sites preventing its degradation, results in extensive hepatocyte apoptosis 
after partial hepatectomy. Although p65 null mice die during embryogenesis, p50-/- mice 
are viable, thus providing a model to study the role of p65/p50 dimer in the regulation of 
cell proliferation and cell apoptotic death. 
Our previous studies have indicated that 2,2’,4,4’,5,5’-hexachlorobiphenyl (PCB-
153), a non-coplanar PCB congener, could activate hepatic NF-κB after a single dose 
(Chapter 2) or during the promotion stage of hepatocarcinogenesis (Tharappel et al. 
2002). In chapter 2, hepatocyte proliferation was induced by PCB-153, which correlated 
the hepatic NF-κB activation in the same animals. Thus, the purpose of this study was to 
determine the role of NF-κB in PCB-induced cell proliferation and the specific proteins 
involved in the pathway. Also, the effects on the apoptotic cell death after treatment with 
non-coplanar PCB in these p50-/- mice were studied.      
 
Materials and Methods 
Materials: 2,2’,4,4’,5,5’-hexachlorobiphenyl (PCB-153) were synthesized and 
characterized as described previously (Schramm et al. 1985).  Vitamin E stripped corn oil 
was obtained from Acros Organics (Morris Plains, NJ). Alzet osmotic pumps (model 
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2ML1) were obtained from Alza Scientific Products, Palo Alto, CA. The anti 5-bromo-
2’-deoxyuridine (BrdU) antibody was purchased from Becton-Dickinson (San Jose, CA). 
The Antigen Retrieval Citra solution was purchased from BioGenex (San Ramon, CA). 
All other chemicals were obtained from Sigma Chemical Co. (St. Louis, MO).  
 
Experimental design and animal treatment: Eight weeks old male F2 (B6.129) mice 
homozygous for NF-κB (p50) mutation and wild type controls were obtained from our 
breeding colony (originally purchased from the Jackson Laboratory, Bar Harbor, ME). In 
the 2-day study, 15 transgenic mice and 15 wild type littermates received a single i.p. 
injection of either corn oil or PCB-153 (300 µmol/kg) and were euthanized 2 days later. 
All mice received an s.c. injection of BrdU (100 mg/kg) 2 hours before euthanasia.  In the 
21-day study, 10 transgenic mice and 18 wild type mice received six i.p. injections of 
corn oil or PCB-153 (100 µmol/kg) and were euthanized four days after the last injection. 
Three days before being euthanized, all mice were surgically implanted s.c. with an 
osmotic pump (Alza Scientific Products, Palo Alto, CA, model 1003D) containing BrdU 
(20mg/ml, 10 µl/hour).   Livers were removed from each mouse and pieces from each 
liver were fixed in 10% formalin and processed for histology and the remaining liver was 
snap frozen in liquid N2 and stored in –80°C.  
 
Nuclear extract preparation: 
Nuclear protein was preparation as described in chapter 2. 
 
Electrophoresis mobility shift assay (EMSA): 
The NF-κB DNA binding activity was measured as described in chapter 2. 
 
BrdU immunohistochemical staining: 
As described in chapter 2. 
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In situ cell death detection assay (TUNEL): 
Reagents: 
1. Hemo-de (Scientific Safety Solvent 15-182-507A) 
2. Ethanol 
3. 10 mM Tris-HCl, pH 7.4-8.0 
4. PBS - as described in chapter 2 
5. Proteinase K  
20 µg/ml, dissolved in 10 mM Tris-HCl, pH 7.4-8.0 
6. H2O2 (Sigma Chemical Co. H0904) 
7. Methyl Green (Vector, H3402) 
8. In situ cell death detection assay kit (Intergen S7101) 
Procedure: 
1. Paraffin slides were incubated in 60 °C oven for 30 minutes. 
2. The slides were washed in Hemo-De 3 times, 5 minutes each time. 
3. The slides were rehydrated through graded series of ethanol (100%, 100%, 95%) and 
water. 
4. The slides were incubated with proteinase K (20 µg/ml in 10 mM Tris/HCl, pH7.4-
8.0), at 37 °C for 15 minutes. 
5. The slides were rinsed with PBS for 2 times, 2 minutes each time. 
6. The slides were incubated with blocking solution (3% H2O2 in PBS) for 5 minutes at 
room temperature. 
7. The slides were rinsed twice with PBS, 5 minutes each time. 
8. Tap off excess liquid and blot around the section 
9. 75 µl of EQUILIBRATION BUFFER was applied on each section, the slides were 
incubated at room temperature for 5 minutes (the company recommend incubate at 
least 10 seconds). 
10. Tap off excess liquid and blot around the sections 
11. Each slide was covered with 50 µl WORKING STRENGTH OF TdT ENZYME (35 
µl of reaction buffer + 15 µl TdT enzyme, 50 µl per slide), the sections were covered 
with the plastic covers came with the kit. The slides were incubate at 37°C for 60 
minutes 
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12. The slides were placed in a staining jar that contained WORKING STRENGTH 
STOP/WASH BUFFER (1 ml STOP/WASH BUFFER + 34 ml H2O), the jar was 
agitated for 15 seconds, then incubated for 10 minutes at room temperature.  
13. The slides were washed in PBS for 3 times, 1 minute each time. 
14. Each section was covered with 65 µl of ANTI-DIGOXIGENIN PEROXIDASE 
CONJUGATE, slides were covered and incubated at 37°C for 30 minutes. 
15. The slides were washed in 4 changes of PBS, 2 minutes per change.  
16. Each section was covered with 75 µl of DAB solution, slides were incubated at RT 
for 3 to 6 minutes. 
17. The slides were rinsed in 3 changes of tap water, and then incubated in running water 
for 5 minutes. 
18.The slides were counterstained in Methyl Green (Vector, H3402) in a staining jar at 
60 °C for 20 minutes. 
19. The slides were washed in running tap water for 5 minutes. 
20. The slides were dipped 5 times in 100% n-butanol, then dipped in 3 changes of 
Hemo-de, 10 dips each change (the exact times of dip have to be optimized to get a 
countable background). 
21. The slides were mounted. 
22. All slides were examined under a light microscopy. At least 2,000 hepatocytes were 
counted each slide, and the incidence of cell undergoing apoptosis was expressed as 
the percentage of number of stained hepatocytes out of the number of total counted 
hepatocytes. 
 
Western blotting: 
Reagents: 
1. 1 M Tris-HCl, pH 6.8 
2. 1 M Tris-HCl, pH 7.4 
3. 1.5 M Tris-HCl, pH 8.8 
4. 5 M NaCl  
5. 15% Sodium deoxycholate  
6. 1 M NaF 
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7. 1 M Na2VO3   
8. 10% Sodium dodecyl sulfate (SDS) (w/v) 
10 g SDS (Sigma Chemical Co. L4390) 
100 ml diH2O 
9. 0.1 M DTT 
10. 10 mg/ml Phenylmethylsulfonyl fluoride (PMSF), (Boehringer Mannheim 837 091)  
      Dissolved in 100% ethanol  
11. 0.33 µg/µl protease inhibitor cocktail 
1 mg aprotinin (Sigma Chemical Co. A1153)   
1 mg leupeptin (Sigma Chemical Co. L2884)   
1 mg pepstatin A  (Sigma Chemical Co. P4265) 
Dissolved in 3 ml of autoclaved water and aliquoted. (pepstatin A was dissolved in 
100 µl DMSO first before adding to cocktail) 
Buffers:  
1. 1 x Phosphate Buffered Saline (PBS), pH 7.4 
 Reagent For 100 ml Final concentration 
Dibasic sodium phosphate (Na2HPO4) 
(Sigma Chemical Co. S5136) 
0.1292 g 9.1 mM 
Monobasic sodium phosphate (NaH2PO4) 
(Sigma Chemical Co. S5011) 
0.0204 g 1.7 mM 
Sodium Chloride (NaCl) 
(Sigma Chemical Co. S3014) 
0.8766 g 150 mM 
    Adjusted pH to 7.4 with NaOH and brought final volume to 100 ml 
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2. Lysis/homogenization buffer for IKKs and IκBs  
Reagent For 25 ml Final Concentration 
Nonidet P-40 (Sigma Chemical Co. 
N6507) 
0.25 ml 1% 
10% SDS 0.25 ml 0.1% 
10 mg/ml PMSF 0.25 ml (add last) 0.1 mg/ml 
Protease inhibitors cocktail  133 µl  (add last) 2 µg/ml 
1x PBS 24.12 ml  
     
3. Lysis buffer for CYP2B1/2, cyclin D1 and Bcl-xL 
Reagent For 20 ml Final Concentration 
1 M Tris-HCl, pH 7.4 1 ml 50 mM 
5 M NaCl  0.6 ml 150 mM 
IGEPAL 0.2 ml 1% 
10% SDS 0.2 ml 0.1% 
15% Sodium deoxycholate 0.667 ml 0.5% 
1 M NaF 1 ml 50 mM 
1 M Na2VO3 0.02 ml 1 mM 
0.1 M DTT 0.2 ml 1 mM 
0.1 M PMSF 0.2 ml 1 mM 
0.33 mg/ml Protease inhibitors 
cocktail  
0.3 ml  (add last) 5 µg/ml 
H2O  15.613 ml  
  
4. Gel loading buffer (2x):  according to Santa Cruz  
Reagent For 5.75 ml Final Concentration 
Glycerol (Sigma Chemical Co. G5516) 1.0 ml 17.3% 
14.3 M β-mercaptoethanol  (Sigma 
Chemical Co. M6250) 
0.5 ml  1.25 M 
10% SDS 3 ml 5.2% 
1 M Tris pH 6.8 1.25 ml 0.22 M 
1-2 mg bromophenol blue   
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 A stock can be made and stored at -20°C with the β-mercaptoethanol. 
5. 10x Running buffer: 
     Reagent For 250 ml Final Concentration 
Tris base 7.575 g 250 mM 
Glycine (Gibco 15527-013) 36 g 1.92 M 
SDS 2.5 g 1% 
6.  1x Transfer Buffer: 
Reagent For 1 liter Final concentration 
Glycine 14.15 g 188 mM 
Tris base 3.0 g 24.8 mM 
100% methanol 200 ml 20% 
   Made fresh and kept at  -20°C until use 
 
7.  10x TBS (pH 7.5): 
Reagent For 1 liter Final concentration 
Tris-base 12.1 g 10 mM 
NaCl 87.6 g 150 mM 
  pH with Hal to 7.5 
8. Wash buffer (TTBS): 
      1x TBS (1 liter)               
      500 µl Tween-20 (0.05% final concentration) (Sigma Chemical Co. P7949) 
9. 5% Blocking buffer (w/v): 
     10 g fat-free dry instant powdered milk       
     200 ml TTBS buffer 
10. 10x Ponceau S stain 
      2 g Ponceau S (Sigma Chemical Co. P3504) 
     30 g trichloroacetic acid (Sigma Chemical Co. T4885) 
     30 g sulfosalicyclic acid  (Sigma Chemical Co. S0640) 
     100 ml H20 
 
Procedure: 
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1. Sample preparation 
The livers were homogenized in 4 folds volume of lysis buffer for 3 x 30 second 
intervals with a 20 second rest in ice between the intervals. The homogenates for the 
IKKs and IκBs were centrifuged at 100,000 g for 1 hour; the homogenates for the 
CYP2B1/2, Bcl-xL and cylcin D1 were centrifuged at 12,000 rpm for 15 minutes. The 
supernants were collected and the protein concentrations were checked using the 
BCA method (Pierce). Samples were aliquoted and frozen at -80°C.  Aliquots were 
mixed with equal volume of the gel-loading buffer (2 x) and placed in boiling water 
for 3-5 minutes to denature the proteins before loading.  
2.  Gel electrophoresis/transfer of proteins  
An 8.5% separating gel and 4% stacking gel were cast in the frame.  25 µg of protein 
was electrophoresed per sample.  A molecular weight marker (10 µl) was run with the 
samples (Bio-Rad 161-0324).  The marker was boiled for 3-5 minutes before using.  
The proteins were electrophoresed with 1x running buffer at 175 volts for 2 hours.  
The proteins in the gels were transferred to nitrocellulose membranes (Gibco 11467-
016) at 100 volts for 1 hour.  
3.   Immunoblotting  
The membranes were blocked with 5% blocking buffer for 1 hour at room 
temperature with shaking.  The membranes were rinsed for five minutes with wash 
buffer before incubating with the primary antibody.   The primary antibody was 
diluted in 5% blocking buffer (20 ml total) and incubated with the membrane for 1 
hour with shaking at room temperature.  The membrane was rinsed with wash buffer 
3 times (5, 5, and 15 minutes).  The secondary antibody was diluted in 5% blocking 
buffer (20 ml total) and incubated with the membrane for 1 hour with shaking at room 
temperature.  The membrane was rinsed 3 times (5, 5, and 15 minutes) with the wash 
buffer.  The following primary and secondary antibodies were used in this study:   
 
Primary antibodies Secondary antibodies 
IκBα Santa Cruz sc-371 (1:1000 
dilutions) 
Anti-rabbit HRP antibody Santa Cruz 
sc-2004 (1:5000 dilution) 
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IκBβ Santa Cruz sc-945 (1:1000 
dilutions) 
Anti-rabbit HRP antibody Santa Cruz 
sc-2004 (1:5000 dilution) 
IKKα/β Santa Cruz sc-7607 (1:1000 
dilutions) 
Anti-rabbit HRP antibody Santa Cruz 
sc-2004 (1:5000 dilution) 
IKKγ Santa Cruz sc-8330 (1:1000 
dilutions) 
Anti-rabbit HRP antibody Santa Cruz 
sc-2004 (1:5000 dilution) 
Cytochrome P450 2B1/2 Oxford 
Biomedical Research PM20 (1:1000 
dilutions) 
Anti-mouse HRP antibody Santa Cruz 
sc-2005 (1:5000 dilutions) 
Cyclin D1 Santa Cruz sc-8396 (1:1000 
dilutions) 
Anti-mouse HRP antibody Santa Cruz 
sc-2005 (1:5000 dilutions) 
Bcl-xL Santa Cruz sc-7195 (1:1000 
dilutions) 
Anti-rabbit HRP antibody Santa Cruz 
sc-2004 (1:5000 dilution) 
β-Actin Santa Cruz sc-1615 (1:1000 
dilutions) 
Anti-goat HRP antibody Santa Cruz 
sc-2768 (1:5000 dilutions) 
 
 
1. Chemiluminescence 
a. 10 ml of the peroxide solution and luminol/enhancer solution from Pierce 
SuperSignal West Pico Chemiluminescent Substrate Kit (34080) were mixed 
together and added to each membrane. 
b. Membrane was incubated with the chemiluminescent mixture for 5 minutes.  The 
detection reagents were drained, and the membranes were covered in plastic wrap 
and exposed to Kodak XOMAT-AR film for 1 minute.  The exposure time can be 
optimized based on original intensity. 
c. The membranes were placed back into the wash buffer and later stripped of the 
antibodies and detection reagents.   
d. The procedure for stripping the membranes was as follows: in a 50 ml tube, 42.55 
ml of 0.235 M Glycine pH 2.2, 5 ml 5M NaCl, 2.45 ml sH2O were mixed 
together.  The membranes were placed in a pre-heated hybridization oven for 5 
minutes at 60°C.  The membranes were removed from the glycine buffer and 
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washed with 0.1M NaOH for 10 minutes at room temperature with shaking.  The 
membranes were rinsed in wash buffer and the proteins were checked with 1x 
Ponceau stain.  The membrane was either dried and stored or re-probed with 
another antibody. 
 
RNA isolation: 
Rageants :  
1.   Trizol Reagent – Life Technologies 15596 
2. Chloroform  
3. Ethanol – Aaper 
4. Isopropyl alcohol – Sigma I-9516 
5. Distilled water RNase, DNase-free – Gibco 10977-015 
Procedure: 
1. Homogenization 
60-80 mg liver tissue was homogenized 1 ml Trizol reagent for 30 seconds using a 
Tekmar homogenizer at 70 output. Incubated homogenized sample at room 
temperature for 5 minutes.  If needed, stored samples at -80°C. 
2.   Phase separation 
The homogenized samples were transferred to a microcentrifuge tube, and 200 µl of 
chloroform was added.  The mixture was shaken vigorously for 15 seconds and 
incubated at RT for 3 minutes.  The samples were centrifuged at 12,000 x g for 15 
minutes at 4°C. 
3.   RNA precipitation  
The top aqueous phase was transferred to a new microcentrifuge tube. 0.5 ml 
isopropyl alcohol was added and mixed gently.  The tubes were incubated at RT for 
10 minutes. The tubes were centrifuged at 12,000 x g for 10 minutes at 4°C. 
4. RNA wash  
The supernatant was discarded, and tubes were allowed to drain on a clean Kim-wipe.  
1 ml 75% ethanol was added.  The tubes were vortexed and centrifuged at 7,500 x g 
for 5 minutes at 4°C. 
5. Redissolving the RNA 
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The 75% ethanol was removed and the pellet was air-dried 10 minutes.  Caution was 
taken to avoid over drying the pellet.  The pellets were dissolved in 100 µl of 
DNase/RNase-free water. The RNA was incubated for 10 minutes at 55°C to dissolve 
completely. The dissolved RNA was aliquoted, and one aliquot was used to determine 
the RNA concentration and purity.  The other aliquots were placed  -80°C freezer 
until needed. 
6. Quantitation and purity of RNA 
The purity of RNA was estimated by reading diluted RNA (1 part of RNA:200 parts 
of TE) with a spectrophotometer. 
The A260/A280 for RNA was around 2. 
Total RNA = (A260)(40 µg/ml)(200) 
  
Ribonuclease protection assay: 
Reagents (all molecular biology grade): 
1. [α-32P]UTP (3000Ci/mmol, 10 mCi/ml) – NEN BLU007H 
2. Tris-saturated phenol, pH 8.0 (Sigma Chemical Co. P4557) 
3. Chloroform:isoamyl alcohol (50:1) 
10 ml chloroform (Sigma Chemical Co. C2432) 
200 µl isoamyl alcohol (ICN 194005) 
4. Mineral oil (Sigma Chemical M5904) 
5. 10X TBE (Gibco 15581-044) 
6. 40% Acrylamide (w/v)  (Gibco 15512-023) 
7. 2% N,N”-Methylenebisacrylamide (w/v) (Gibco 15516-016) 
8. Urea (Gibco 15505-035) 
9. Ultrapure, RNase-free H2O  (Gibco 10977-015) 
10. 100% Ethanol (Aaper) 
11. Ammonium persulfate  (Sigma Chemical Co. A9164) 
12. Dimethyldichlorosilane (Sigma Chemical Co. D3879) keep in 4°C 
13. TEMED (Sigma Chemical Co. T7024) 
Supplies: 
1. RiboQuant ™ RNase Protection Assay Kit  - Becton Dickinson Pharmingen    
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        556134  
2. MCYC-1 RiboQuant ™ Mouse Cyclin Multi-Probe Template set – Becton Dickinson 
Pharmingen 556241  
3. RiboQuant ™ In Vitro Transcription Kit – Becton Dickinson Pharmingen 556850  
4. RNase-free 1.7 ml microcentrifuge tubes, pipette tips, and plastic ware 
5. RNase-free glassware (baked for at least 4 hours at 150°C) 
6. Gel blotting paper – Schleicher & Schuell # 31540 
Probe Synthesis: 
1. The following were added to a microcentrifuge tube: 
1 µl RNasin 
1 µl GACU pool 
2 µl DTT 
4 µl 5x transcription buffer 
1 µl RPA Template set (Pharmingen mCYC-1 RiboQuant Multi-Probe  
 556241) 
      10 µl [α-32P]UTP 
      1µl T7 RNA Polymerase 
The contents were mixed by flicking and given a quick spin in a microcentrifuge.  
The reaction was incubated for one 1 hour at 37°C in heat block. 
2. To stop the reaction, 2 µl of DNase were added to the reaction.  The tube was mixed 
by flicking and spun quickly.  The tube was incubated 30 minutes at 37°C. 
3. The following were added to the microcentrifuge tube: 
26 µl 20 mM EDTA 
25 µl Tris-saturated phenol, pH=8.0 
25 µl chloroform:isoamyl alcohol (50:1) 
2.6 µl tRNA  
The tube was mixed by vortexing into an emulsion and spun at 12,000 rpm in 
microcentrifuge for 5 minutes at room temperature. 
4. The upper aqueous phase was transferred to a new microcentrifuge tube. 50 µl 
chloroform:isoamyl alcohol was added.  The tube was mixed by vortexing and spun 
at room temperature for 2 minutes at 12,000 rpm.   
5. The upper aqueous phase was transferred to a new tube.  In order to precipitate the 
RNA probe, 50 µl 4 M ammonium acetate and 250 µl ice-cold 100% ethanol were 
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added to the tube.  The tube was inverted and incubated overnight at -80°C.  The 
tube was spun at maximum speed in a microcentrifuge for 15 minutes at 4°C. 
6. The supernatant was removed and added 100 µl of cold 90% ethanol was added to 
the small pellet.  The tube was spun in a microcentrifuge for 5 minutes at 4°C. 
7. Being careful not to disturb the pellet, the supernatant was removed and the pellet 
was air dried for 10 minutes.  The pellet was dissolved in 50 µl of the hybridization 
buffer and vortexed gently for 20 seconds followed with a quick spin. 
8. Using a scintillation counter, 1 µl of the probe was quantified.  The average counts 
of the labeled probe were 2x105 Cherenkov counts/µl (measurement of cpm/µl in the 
absence of scintillation fluid).  The probe was stored at -20°C and was usable up to a 
week.  
RNA Preparation and Hybridization: 
9. One aliquot of each sample of RNA was removed from -80°C freezer and 15 µg of 
RNA were added to a new microcentrifuge tube.  As a background control, one tube 
containing 1.2 µl of yeast tRNA.  To serve as a positive RNA integrity control, 
another tube contained 2 µl of the PharMingen mouse control RNA (556213). 
10. The RNA was placed in -80°C freezer for 15 minutes.  The RNA was dried in 
a vacuum evaporator centrifuge for 30 minutes without heat.   
11.  8 µl of hybridization buffer was added to each sample and vortexed for 3 
 minutes followed with a quick spin. 
12. The mCYC probe was diluted to 1.15 x 105 count/µl. 2 µl of diluted probe was added 
to each RNA sample and mixed by gently flicking the tube.  One drop of mineral oil 
was added to each tube and all tubes were given a quick spin.      
13. All samples were placed in a 90°C heat block.  The temperature was immediately 
adjusted to 56°C, and the samples were incubated 12-16 hours.  Fifteen minutes 
before starting the RNase treatments, the heat block was adjusted to 37°C, allowing 
the temperature to ramp down slowly.   
RNase Treatments: 
14. For 26 samples, prepared the RNase cocktail: 
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2.8 ml RNase buffer + 6.0 µl (RNase + T1 mix) were combined and 100 µl of the 
cocktail was added to each sample (under the mineral oil).  All samples were given a 
quick spin and incubated at 30°C for 45 minutes. 
15. During the RNase digestion, the Proteinase K cocktail was prepared.  For 26   
samples the following were combined: 
421.2 µl Proteinase K buffer 
32.4 µl Proteinase K    
32.4 µl yeast tRNA   
All mixed together and 18 µl cocktail was added to a new tube for all samples  
16. 105 µl of the RNase digests were carefully removed and transferred to the 18 µl 
aliquot of Proteinase K cocktail.  The samples were quickly vortexed spun, and 
incubated for 15 minutes at 37°C. 
17. The following were added to each sample: 
65 µl Tris-saturated phenol  
65 µl chloroform:isoamyl alcohol (50:1)  
 The mix was vortexed and spun in microcentrifuge for 5 minutes at room 
temperature at max speed 
18. The upper aqueous phase (120 µl) was transferred to a new tube (avoiding organic 
interface), and 120 µl 4 M ammonium acetate and 650 µl ice-cold 100% ethanol 
were added.  The tubes were inverted and incubated for 30 minutes at -70°C.  The 
tubes were spun at maximum speed for 15 minutes at 4°C.   
19.  Avoiding the pellet, the supernatant was removed.  100 µl ice-cold 90% ethanol was 
added the supernatant, and the tubes were spun at maximum speed for 15 minutes at 
4°C in microcentrifuge. 
20. The supernatant was carefully removed and the pellets were air-dried.  5 µl of the 1x 
loading buffer was added to each tube, vortexed for 2 minutes, and given a quick 
spin in a microcentrifuge.  Before loading samples for electrophoresis, the samples 
were heated at 90°C for 3 minutes and placed into an ice bath. 
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Electrophoresis: 
21. A set of clean glass plates (19 cm x 19.7 cm) was rinsed thoroughly with RNase free 
water then with ethanol.  The short plate was siliconized and cleaned again.  The 
plates were assembled.   
22. A 5% acrylamide gel (19:1 acrylamide/bis) was prepared (45 ml): 
5.31 ml 40% acrylamide 
5.58 ml 2% bis acrylamide 
4.47 ml 10X TBE 
21.5 g Urea (8M final) 
brought volume to 44.69 ml with DEPC-treated water  
270 µl 10% ammonium persulfate (APS) 
36 µl TEMED 
The acrylamide mixture was poured immediately into gel assembly. The gel 
polymerized for at least 1 hour. 
23. The comb was removed and the wells were thoroughly flushed with 0.5X TBE.  The 
gel was pre-run for 45 minutes at 250 volts with 0.5X TBE as the running buffer.  To 
avoid overheat, the gel was run at 4°C.   
24. Before loading the samples, the wells were flushed again with 0.5X TBE.  The 
samples were loaded into each well, and a dilution of free probe was run with the 
samples (in 1x loading buffer) to serve as a size marker (1000-2000 cpm/lane). 
25. The gel was run at 300 volts for 2 ½ hours. The first dye band (bromophenol blue) 
ran off the gel. 
26. The gel plates were disassembled, and the gel was transferred to pre-cut gel blotting 
paper.  The gel was wrapped with plastic wrap dried on a gel dryer (Owl Scientific 
#GD-3) under vacuum for 1 hour at 80°C.  The dried gel was placed on a 
phosphorimaging screen (Molecular Dynamics) for at least 4 hours.  The screen was 
scanned into a phosphorimager, and the radioactivity was counted using the 
ImageQuant 5.0 software.   
27. Using semi-log graph paper, the undigested (free) probe was plotted with the 
migration on the x-axis and the log nucleotide length on the y-axis, thus creating a 
standard curve.  The migration of the RNase-protected bands was plotted on the 
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standard, and the nucleotide length was calculated (estimated).  This value was 
compared to the actual length of each protected probe, thereby correctly identifying 
each band.  
 
Statistical analysis:   
Results were first analyzed by a two-way analysis of variance.  Individual 
differences between means were determined using the Bonferroni post hoc test.  The 
results were reported as means + standard error of mean (SEM).  The level of 
significance was p ≤ 0.05. 
 
Results 
Body weight and liver weight 
 In the 2-day study, there was no significant difference in the body weight or liver 
weight among all groups (Table 3.1). In the 21-day study, the body weights of p50-/- 
mice were significantly less than those of wild type mice. PCB-153 treatment 
significantly increased the liver weight and relative liver weight (percentage of body 
weight) in both p50-/- mice and wild type mice. 
 
Hepatic cytochrome P450 2B1/2 (CYP2B1/2) protein 
 The protein level of CYP2B1/2 in the liver was measured with Western blotting. 
There was no difference in the hepatic protein level of CYP2B1/1 between p50-/- mice 
and wild type mice (Figure 3.1). PCB-153 slightly increased the protein level of 
CYP2B1/2 in wild type mice and in p50-/- mice in both studies. 
  
Hepatic NF-κB activity   
 In the 2-day study, the hepatic DNA binding activity of NF-κB was significantly 
increased by PCB-153 in wild type mice (Figure 3.2), but not in p50-/- mice. The protein 
levels of IKKs (IKKα, IKKβ, IKKγ) and IκBβ were not changed by PCB treatment, and 
there was no difference in these proteins between wild type mouse and p50-/- mouse 
(Figure 3.3). There was less IκBα protein in p50-/- mouse than in wild type, but IκBα 
protein was not affected by PCB-153 treatment. 
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 In the 21-day study, the hepatic DNA binding activity of NF-κB was higher in 
wild type mice than p50-/- mice (Figure 3.4), and there was no difference in NF-κB 
activity between PCB-treated animals and corn oil-treated controls. As in the 2-day study, 
the protein levels of IKKs (IKKα, IKKβ, IKKγ) and IκBβ were not changed by PCB 
treatment (Figure 3.5), and there was no difference in these proteins between wild type 
and p50-/- mice. There was less IκBα protein in p50-/- mice than in the wild types, and 
IκBα protein was not affected by PCB-153 treatment.                                                                                  
 
Hepatocyte proliferation and apoptosis 
 In the 2-day study, PCB-153 treatment increased hepatocyte proliferation in wild 
type mice significantly (p < 0.05), but not in p50-/- mice (Figure 3.6). In the 21-day 
study, PCB-153 treatment increased hepatocyte proliferation significantly in wildtypes (p 
< 0.05); in the p50-/- mice there was a slight increase (Figure 3.7). 
 Apoptosis in hepatocytes was measured by the TUNEL assay. The apoptotic 
index was much higher in p50-/- mice than in wild type mice (p < 0.05), and this increase 
was blocked by PCB-153 in both studies (Figure3.8, 3.9), with a more pronounced effect 
in the 21-day study (p < 0.05).  
 
mRNA and protein levels of  cyclins    
 The mRNA levels of cyclin A2, B1, B2, C, D1 and D2 in liver were measured 
using RNase protection assay (RPA) (Table 3.2). For all the cylcins studied, there were 
no significant differences between wild type mice and p50-/- mice in both studies. PCB-
153 significantly decreased the mRNA level of cyclin A2, B1, B2, and C in the 2-day 
study (p < 0.05), but not that of cyclin D1 or D2; in the 21-day study, the mRNA level of 
all cyclins were not significantly different among the groups.   
 The protein level of cyclin D1 was measured with Western blotting. Compared to 
wild type mice, p50-/- mice had less cyclin D1 protein in the liver (Figure 3.10). The 
protein level of cyclin D1 in the liver was not changed by PCB-153 in either study.  
 
Bcl-xL protein  
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 The protein level of Bcl-xL in the liver was measured with Western blotting. In 
either study, there was no difference in the protein level of Bcl-xL in the liver among any 
groups (Figure 3.11).  
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Table 3.1 Effect of PCB-153 on the body and liver weights of the p50-/- mice and 
wild type mice 
________________________________________________________________________ 
 
Genotype Treatment  Body weight   Liver weight           Liver weight  
            (g)           (g)     (% of body weight) 
________________________________________________________________________ 
 
2 days 
Wild type  corn oil 25.64 + 0.73  1.32 + 0.07           5.15 + 0.27 
 PCB-153 25.51 + 0.50  1.48 + 0.06           5.79 + 0.15 
p50-/-   corn oil 24.27 + 0.99  1.53 + 0.09           6.30 + 0.18 
PCB-153 22.61 + 0.61  1.39 + 0.05           6.12 + 0.08 
________________________________________________________________________ 
 
21 days 
 
Wild-type corn oil   29.65 + 0.62            1.55 + 0.06             5.24 + 0.18       
  PCB-153   31.41 + 0.91             1.77 + 0.10+           5.63 + 0.25+ 
p50-/-   corn oil   25.65 + 1.24*           1.54 + 0.09           5.99 + 0.11* 
  PCB-153   25.37 + 1.21* 1.71 + 0.09+           6.73 + 0.20+* 
________________________________________________________________________ 
 
Results are expressed as mean + SEM. Each group contained 5-10 animals. *Values are 
significantly different from wild type mice. +Values are significantly different from 
respective controls treated with corn oil. (p < 0.05). 
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Figure 3.1. Protein levels of CYP2B1/2 in the 2-day and 21-day studies. A. Western blot 
was performed using an antibody specific for CYP 2B1/2 with liver homogenates from 
mice treated with corn oil, or PCB-153 (300 µmol/kg in the 2-day study, 100 µmol/kg for 
6 injections in the 21-day study). Each lane contains protein from a single mouse (25 µg). 
B. Relative amount of CYP 2B1/2 protein from the Western blotting data as shown in A.  
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Figure 3.2. Effect of PCB-153 on hepatic DNA binding activity of NF-κB in the 2-day 
study. A. EMSAs were performed using a radiolabeled NF-κB oligonucleotide with  liver 
nuclear extracts from individual mice. Each line contains extracts from a single mouse (5 
µg). B. Net radioactive counts of NF-κB bands from the EMSA data shown in A. 
Quantitation of the specific NF-κB band was determined by subtracting background 
counts from the counts in each NF-κB band. *Values are significantly different from 
other groups (p < 0.05). 
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Figure 3.3. Protein levels of cytosolic IκB and IKK in the 2-day study. Each line 
contains cytosolic protein from a single animal (25 µg). 
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Figure 3.4. Effect of PCB-153 on the hepatic DNA binding activity of NF-κB in the 21-
day study. A. EMSAs were performed using a radiolabeled NF-κB oligonucleotide with 
liver nuclear extracts from individual mice. Each line contained extracts from a single 
mouse (5 µg). B. Net radioactive counts of NF-κB bands from the EMSA data shown in 
A. Quantitation of the specific NF-κB band was determined by subtracting background 
counts from the count in each NF-κB band. *Values are significantly different from other 
groups (p < 0.05). 
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Figure 3.5. Protein levels of IκB and IKK proteins in the 21-day study. Each line 
contains cytosolic protein from a single mouse (25 µg). 
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Figure 3.6. Effect of PCB-153 on hepatocyte proliferation in the 2-day study. Mice were 
administrated BrdU by a s.c. injection of BrdU two hours before the euthanasia. Tissue 
sections were immunohistochemically stained for BrdU and the labeling index was 
determined. Each group contained 5-10 animals. *Values are significantly different from 
other groups (p < 0.05). 
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Figure 3.7. Effect of PCB-153 on hepatocyte proliferation in the 21-day study. Mice 
were administrated BrdU by a 3-day infusion using Alzet osmotic pump. Tissue sections 
were immunohistochemically stained for BrdU and labeling index was determined. Each 
group contained 5-9 animals. a, b Groups with different letters are significantly different 
(p < 0.05). 
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Figure 3.8. Effect of PCB-153 on hepatocyte apoptosis in the 2-day study. Liver section 
were immunostained using the TUNEL method, and apoptotic index was determined for 
each mouse. Each group contained 5-10 animals. *Values are significantly different from 
other groups (p < 0.05). 
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Figure 3.9. Effect of PCB-153 on hepatocyte apoptosis in the 21-day study. Liver section 
were immunostained using the TUNEL method, and apoptotic index was determined for 
each mouse. Each group contained 5-9 animals. a, b, c Groups with different letters are 
significantly different (p < 0.05). 
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Table 3.2. Effect of PCB-153 on hepatic cyclin mRNA expression in p50-/- mice and 
wild type mice in the 2-day and 21-day studies 
 
                
          cyclins   mRNA (%)     
Genotype Treatment A2 B1 B2 C D1 D2 
2 days        
Wildtype corn oil 15.86 + 0.61 12.00 + 0.52 29.45 + 0.77 22.06 + 0.65 21.01 + 2.80 21.49 + 0.34
 PCB-153 14.36 + 0.45* 11.04 + 0.75* 27.39 + 0.95* 20.54 + 0.22* 28.26 + 3.78 19.95 + 0.80
p50-/- corn oil 16.65 + 1.17 13.62 + 1.36 29.43 + 1.00 21.91 + 0.86 22.11 + 4.80 22.49 + 0.55
 PCB-153 13.33 + 0.40* 10.03 + 0.37* 26.95 + 5.30* 19.29 + 0.08* 28.60 + 4.68 20.52 + 1.64
        
21 days         
Wildtype corn oil 11.84 + 0.56 10.13 + 0.44 28.24 + 1.59 16.95 + 0.78 27.65 + 4.05 21.99 + 1.10
 PCB-153 12.51 + 0.84 10.92 + 0.56 27.66 + 0.22 18.06 + 0.84 20.33 + 0.89 21.46 + 0.89
p50-/- corn oil 11.92 + 0.69 10.15 + 0.46 30.99 + 0.45 18.81 + 0.67 25.26 + 2.78 22.08 + 1.25
  PCB-153 11.81 + 0.79 10.28 + 1.15 29.29 + 2.96 18.36 + 1.58 22.17 + 2.50 21.76 + 1.97
        
Results are expressed as the percentage of the control (L32). Numbers are shown as the 
mean + SEM with n = 3 for each group. *Values are significantly different from 
respective corn oil-treated controls (p < 0.05) 
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Figure 3.10. Protein level of cyclin D1 in the 2-day and 21-day studies as determined by 
Western blotting. Each line contains protein from a single mouse (25 µg). 
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Figure 3.11. Protein level of Bcl-xL in the 2-day and 21-day studies as determined by 
Western blotting. Each line contains protein from a single mouse (25 µg). 
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Discussion 
 Recent studies have indicated that PCB mixtures and specific PCB congeners can 
cause an increase in cell proliferation and an inhibition of apoptosis in rodent liver or 
hepatocytes (Bohnenberger et al. 2001; Haag-Gronlund M 2000; Kolaja et al. 2000; 
Tharappel et al. 2002; Whysner & Wang 2001). PCB-118, PCB-77 and Aroclor 1254, a 
PCB mixture, have all been found to induce hepatocyte proliferation during 
hepatocarcinogenesis. Also, our previous work showed an increase in hepatocyte 
proliferation after a single dose of PCB-153 (Chapter 2). The purpose of this study was to 
elucidate the role of NF-κB in the regulation of hepatocyte proliferation and inhibition of 
apoptosis. 
 In the 2-day study, PCB-153 increased hepatic NF-κB activity by PCB-153 in 
wild type mice, but not in p50-/- mice, which was not surprising since both p50 and p65 
are present in the NF-κB protein-DNA binding complex. The IKKs and IκBs proteins 
were no changed by PCB-153, suggesting the presence of an IκB-independent NF-κB 
activation pathway. The protein level of IκBα was lower in p50-/- livers compared to 
p50+/+ livers, possibly reflecting a compensatory response to the loss of p50/p65 
activity. Unlike the 2-day study, the hepatic NF-κB activity in wild type mice was not 
induced by PCB-153 in the 21-day study, but the higher activity of NF-κB in these mice 
compared to p50-/- mice suggested stresses caused by the multiple i.p. injections in those 
mice. 
PCB-153 increased hepatocyte proliferation in wild type mice, but not in p50-/- 
mice in the 2-day study, which showed that NF-κB (p50/p65) is important in the 
regulation of PCB-153-induced cell proliferation. Studies have shown normal liver 
regeneration in p50-/- mice (DeAngelis et al. 2001), as the result of a compensatory 
effect increase in the p65 subunit of NF-κB. In our 2-day study, p50-/- livers contained 
the same low level of NF-κB activity as in wild type livers; this could be explained by 
overexpression of p65 with the formation of p65 homodimers, or by the binding of p65 to 
other NF-κB family members. An increase in p65 or other NF-κB family members and 
the decreased amount of IκBα in p50-/- livers would explain the increase in DNA 
synthesis at later time point, as shown in the 21-day study.  IκBα is an important target 
 97
 
gene of p50/p65 that down-regulates NF-κB activity. The reduced down-regulation of 
p65 could compensate for the absence of p50. However, p65 cannot fully compensate for 
the p50 deficiency, as shown in the low level of DNA synthesis in the single dose PCB-
treated p50-/- livers and the higher incidence of apoptosis in p50-/- livers.    
Hepatocytes typically proliferate at a very low rate, yet increased proliferation 
occurs in response to physical, infectious or toxic injury (Kitamura et al. 1998)].  The cell 
cycle control system is regulated by the expression of cyclins, cyclin-dependent kinases 
(CDKs) and cyclin-dependent kinase inhibitors (CKIs).  Control of mammalian cell 
proliferation by extracellular signals takes place in the mid- to late- G1 phase of cell 
cycle. Cyclin D, in association with CDK4 and CDK6, as well as cyclin E/CDK2, 
promotes the G1-to-S phase transition by phosphorylating retinoblastoma protein (pRB), 
hyperphosphorylations of pRB release the transcription factor E2F, which is required for 
the activation of S-phase-specific genes (Bartek J 1996; Beijersbergen RL 1996). 
Transcriptional activation of the cyclin D1 gene occurs through the Ras signaling 
pathway via MAPKs, ERK1 and ERK2 (Lavoie et al. 1996). In addition, accumulating 
data show that NF-κB binding to the cyclin D1 promoter is critical for cyclin D1 
transcription initiation and hyperphosphorylation of pRB (Hinz et al. 1999) (Guttridge et 
al. 1999; Henry et al. 2000; Joyce et al. 1999). The overexpressions of Cyclin D1 has 
been observed in hepatocellular carcinoma (HCC) (Joo et al. 2001); studies with 
transgenic mice model show that targeted overexpression of cyclin D1 leads to the 
development of mammary carcinomas (Wang et al. 1994) and hepatocellular carcinoma 
(Deane et al. 2001). Hepatocyte cyclin D1 expression can be increased by the hepatic 
tumor promoters nafenopin (Chevalier & Roberts 1999) and phenobarbital (Kinoshita et 
al. 2002), which suggests that changes in the cyclins/CDK complexes and the CKIs could 
result in the loss of regulation of hepatocyte proliferation. In our studies, we compared 
the change in the mRNA level of cyclin A2, B1, B2, C, D1 and D2. There was no 
significant change in the cyclin D1 mRNA level between wildtype and p50-/- livers, or 
after PCB-153 treatments, but there was less cyclin D1 protein in p50-/- livers than in the 
wild type livers. The lack of paralleled changes between mRNA and protein levels of 
cyclin D1 has been described early in regenerating liver after partial hepatectomy 
(Albrecht et al. 1995) and in adult rat liver (Awad & Gruppuso 2000). Cyclin D1 mRNA 
 98
 
was highly induced in rat liver after partial hepatectomy, while the protein levels changed 
< 2 fold and did not parallel changes in the mRNA (Albrecht et al. 1995). In adult rat 
livers, the mRNA levels of cyclin D1 were present as a higher level than in fetal livers, 
while the protein was absent in adult livers, in which a posttranscriptional regulation was 
indicated (Awad & Gruppuso 2000). How the absence of p50 protein decreases Cyclin 
D1 at the protein level but not the mRNA level remains unclear, but our data do suggest 
an important role of Cyclin D1 posttranslational regulation in hepatocyte growth 
regulation.  
The suppression of apoptosis is another important mechanism by which 
nongenotoxic hepatocarcinogens may induce cancer. The tumor promoters phenobarbital 
and non-coplanar PCBs have been shown to inhibit UV-induced apoptosis in primary 
hepatocytes (Bohnenberger et al. 2001). Tharappel et al. have shown inhibition of 
apoptosis by PCB-153 in focal hepatocytes in an initiation-promotion study (Tharappel et 
al. 2002). Salvi et al. have shown that PCBs inhibit the mitochondrial permeability 
transition and the consequent release of cytochrome C from mitochondria (Salvi & 
Toninello 2001). Considering the pivotal role of cytochrome C in caspase activation, 
inhibition of its release would indicate an interruption of apoptotic pathway. However, 
there are few quantitative data on apoptosis in mouse liver and little is known about its 
regulation in hepatocytes. In the studies by DeAngelis et al. (DeAngelis et al. 2001), 
analysis of apoptosis in p50-/- livers showed a small increase in overall apoptosis in the 
absence of p50, in which Fas antibody was used to activate the Fas receptor pathway and 
induce apoptosis, but apoptosis in untreated livers was not reported in that study. In our 
study, we showed that a very low number of hepatocytes were undergoing apoptosis in 
wild type mice, while p50-/- livers showed more apoptosis. Although this increase in 
spontaneous apoptosis is not as severe as that in the p65 knockout mouse, which causes 
massive hepatocyte apoptosis and embryonic death (Beg et al. 1995), it demonstrated the 
importance of NF-κB (p50/p65) as anti-apoptotic mediators.  
Studies have demonstrated that Bcl-2 family members were involved in the 
inhibition of apoptosis by phenobarbital and peroxisome proliferators in primary 
hepatocytes and mouse liver (Christensen et al. 1998; Christensen et al. 1999; Sanders & 
Thorgeirsson 1999), which suggested a possible mechanism of NF-κB as anti-apoptotic 
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mediator in liver. Bcl-2 family members are mitochondrial membrane proteins; Bcl-2 and 
Bcl-xL inhibit release of cytochrome C from mitochondria and act as anti-apoptotic 
proteins, while Bax and Bak are apoptosis-inducing proteins. The precise mechanism by 
which these proteins regulate cell death is still under investigation. However, the cellular 
equilibrium between inducing and inhibiting proteins is important in determining cell 
fate. Both the human and mouse Bcl-xL promoters contain NF-κB binding sites (Lee et 
al. 1999; Tamatani et al. 1999), and this binding of NF-κB is important in Bcl-xL 
expression and for the anti-apoptotic effects at least in immune CD40 cells (Lee et al. 
1999).  But we did not find any change in the protein level of Bcl-xL by PCB-153 in the 
present study, and there was no difference in the Bcl-xL protein between p50-/- and wild 
type livers. Christensen et al. have shown that acute treatment with phenobarbital resulted 
in an induction of Bcl-2 protein levels in mouse livers, but Bcl-xL was not changed 
(Christensen et al. 1999). However, the same study showed increased Bcl-xL expression 
in altered hepatic foci (AHF), adenomas and carcinomas after long-term treatment with 
phenobarbital. 
 In summary, our data support the hypothesis that NF-κB activation plays a central 
role in regulation of cell proliferation and inhibition of apoptosis in liver, and that the 
activation of NF-κB by PCBs may contribute to the tumor promoting activity of non-
coplanar PCBs congener PCB-153.  
 100
 
Chapter 4. Effect of dietary vitamin E on cell proliferation and 
transcription factor NF-κB activation during the promotion of liver 
carcinogenesis by Polychlorinated Biphenyls (PCBs) 
 
Introduction 
Polychlorinated biphenyls (PCBs) are persistent environmental contaminants and 
bioaccumulate in the food chains, thus posing a health hazard to animals and humans 
(Safe 1994; Silberhorn et al. 1990).  There are 209 possible congeners of PCBs, the toxic 
effects and physical properties of a PCB congener are dependent on the molecular 
structure. Coplanar PCBs are PCB congeners that are substituted in both para and at least 
two meta positions but not in any of the ortho positions, they may form a coplanar 
configuration similar to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and bind strongly to 
Ah receptor. The toxic effects of coplanar PCBs include immunological and reproductive 
effects, hepatic toxicities such as hepatimegaly, induction of cytochrome P4501A1 and 
1A2 (CYP1A1, CYP1A2). On the other hand, PCBs with chlorine substitutes in two 
ortho-positions are non-coplanar, have low affinity to Ah receptor; they induce the 
cytochrome P450 2B1 and 2B2 (CYP2B1, CYP2B2), and some of them are neurotoxic 
(Fischer et al. 1998). Previous studies showed that PCB mixtures or individual congeners 
can act as tumor promoters (Glauert 2001; Silberhorn et al. 1990), but the exact 
mechanisms are still unclear.  
The development of liver carcinogenesis process can be divided into at least three 
consecutive phases: initiation, promotion, and progression (Dragan et al. 1993). The first 
step, initiation, results from a genetic change, which could be due to a chemical, physical, 
or microbial agent.  The genetic alteration is irreversible; however, the initiated 
phenotype is not fully expressed unless the cell is promoted, which is the second step of 
carcinogenesis. The promotion stage involves a reversible clonal expansion of single 
initiated cells. A fraction of hepatic focal lesions represent the precursor to hepatic cancer 
in the evolution of hepatocellular carcinoma. Progression is the final stage of 
carcinogenesis and occurs when a neoplasm develops into a benign or a malignant 
neoplasm. Tumor promoters are a group of compounds that can enhance the growth of 
hepatic focal lesions by changing cell proliferation and cell death. Tumor promoters, such 
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as phenobarbital and peroxisome proliferators, do not interact directly with genomic 
DNA, but chronic administrations of these compounds cause the increased incidence of 
hepatic tumors (Bayly et al. 1994; Cunningham 1996; Gill et al. 1998; Roberts et al. 
1995; Shane et al. 2000). The exact mechanisms by which tumor promoters exert their 
promoting activities are still unknown. Mechanisms have been proposed for the change in 
growth of hepatic focal lesion caused by tumor promoters, including the inhibition of 
apoptosis and induction of cell proliferation  
 The formation of reactive oxygen species (ROS) and is one of mechanisms by 
which tumor promoters may promote hepatic tumors. Several studies have shown that 
PCBs can cause oxidative damages, in forms of lipid peroxidation (Kamohara et al. 1984; 
Pelissier et al. 1990; Saito 1990), modulation of antioxidants status and antioxidant 
enzymes (Peltola et al. 1994; Twaroski et al. 2001b), and oxidative DNA damages 
(Srinivasan et al. 2001).  Oxidative stress caused by tumor promoters can alter gene 
expression. For example, the transcription factor NF-κB has been shown to be activated 
by PCBs (Tharappel et al. 2002). Vitamin E, the major lipophilic chain-breaking 
antioxidant, is thought to act as a chemopreventive agent at the initiation and the 
promotion stage.  By blocking nitrosamine formation (Ohshima et al. 1982) or by 
inhibiting DNA injury (McVean & Liebler 1999), vitamin E can block initiation, and 
vitamin E may inhibit promotion by acting on the immune system or by decreasing cell 
proliferation (Kishimoto et al. 1998; van Poppel & van den Berg 1997)   
 In this study, the effect of dietary α-tocopherol acetate on PCBs-induced hepatic 
focal lesion growth in diethylnitrosamine (DEN)-initiated Sprague-Dowley rats was 
investigated. The PCBs used in this study were 3,3’,4,4’-tetrachlorobiphenyl (PCB-77), a 
coplanar PCB, and 2,2’4,4’,5,5’-hexachlorobiphenyl (PCB-153), a non-coplanar PCB.  
Rats were fed purified diet containing different levels of α-tocopherol acetate (10, 50, or 
250 ppm) and administrated four doses of corn oil, PCB-77, or PCB-153 after an 
initiating dose of DEN. The hepatic DNA binding activity of NF-κB was determined. 
The rates of cell proliferation were measured, both in normal hepatocytes and in placental 
glutathione S-transferase (PGST)-positive cells. 
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Materials and methods 
Materials: 3,3’,4,4’–tetrachlorobiphenyl (PCB-77) and 2,2’,4,4’,5,5’-hexachlorobiphenyl 
(PCB-153) were synthesized and characterized as described previously (Schramm et al. 
1985). Tocopherol-stripped corn oil was from Acros Organics (Morris Plains, NJ). All 
dry constituents of the purified diet were from Teklad Test Diets (Madison, WI). Alzet 
osmotic pumps (model 2ML1) were from Alza Scientific Products, Palo Alto, CA. The 
anti 5-bromo-2’-deoxyuridine (BrdU) antibody was purchased from Bection-Dickinson 
(San Jose, CA). The anti-placental glutathione S-transferase (PGST) antibody was 
purchased from Novocastra Laboratories Ltd. (New Castleupon Tyne, England). The 
Vectastain staining kit was from Vector Laboratories (Burlingame, CA). The α-
tocopherol acetate and other chemicals were from Sigma Chemical Co. (St. Louis, MO). 
 
Experimental design and animal treatment: Eighty-one female Sprague-Dawley rats 
(200 grams) were obtained from Harlan Sprague Dawley (Indianapolis, IN) and housed 
three rats per cage in a temperature and light-controlled room. The rats were allowed to 
acclimatize for one week before starting the experiment. After one week, the rats were 
initiated with diethylnitrosamine (DEN, 150 mg/kg) and were divided into 3 groups (27 
rats per group) and placed on a purified diet (see Table 1) containing 10, 50, or 250 ppm 
vitamin E (α-tocopherol acetate). The rats received the diet ad libitum. After one week on 
the purified diet, rats received an intraperitoneally (i.p.) injection of corn oil, PCB-77, or 
PCB-153. The rats received another 3 i.p. injections every two weeks, and were 
euthanized 10 days after the last injection. Alzet osmotic pumps (containing 20 mg/ml 
BrdU) were surgically implanted in each rat two days before euthanasia. Liver pieces 
were removed and fixed in 10% formalin, the rest of the liver was frozen in liquid 
nitrogen and stored in –80 °C until time of assay. 
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Table 4.1. Composition of purified diets 
________________________________________________________________________ 
Constituents      percent of diet   
________________________________________________________________________        
                
Casein (vitamin free)     14.0 
Corn starch       46.57 
Dextrose monohydrate     25.5 
Cellulose fiber      5.0 
Corn oil (tocopherol stripped)   4.0 
AIN mineral mix      3.5 
L-cystine      0.18 
Choline bitartrate     0.25 
AIN vitamin mix without vitamin E   1.0 
a-tocopheryl acetate    10, 50, or 250 ppm     
 
Measurement of  α-tocopherol: 
Principle: Tocopherols were extracted from liver homogenates with hexane, and 
measured using fluorescence detector in a HPLC system. 
Chemicals:  
1. 100% Ethanol  
2. Hydrochloric acid (Fisher Scientific A144-500) 
3. Hexane (Fisher Scientific H303-4)   
4. Nitrogen Gas 
5. Methanol (Mallinckrodt ChromAR HPLC Grade 3041)  
6. α-dl-tocopherol standard (Lancaster Synthesis 9231)   
Other supplies: 
7. Gelman Acrodisc 13 mM with 0.2 µM nylon membrane (Gelman Sciences 4427) 
8. HPLC vials for autoinjector (Fisher Scientific 03-375-3E) 
9. Inserts for HPLC vials (Sun Brokers 200-232, this is only needed if the sample 
volume is less than 300 µl) 
10.  Pyrex glass tubes 9826 
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11.  0.22 µM Nycaflo nylon membrane filters – Gelman Sciences 66602   
Sample preparation: 
1. The frozen liver tissues were homogenized with 3-fold volume of 1.15% KCl with 
0.1 mM EDTA, pH 7.4. The tissues were placed in a 15 ml tube and homogenized for 
20 seconds at 60 output using an Ultra-Turrax homogenizer (Tekmar Co, Cincinnati, 
OH). The homogenates were aliquoted and kept at –80 °C freezer. 
2. 300 µl aliquot was removed from –80 °C freezer and placed in ice. 
3. The following were added to a screw cap Pyrex tube:   
1.2 ml 95% Ethanol  
60 µl 0.1 N HCl 
3.6 ml hexane 
300 µl homogenate 
4. Each tube was vortexed for 20 seconds using Vortex Genie, then all samples were 
vortexed for 5 minutes. 
5. The samples were spun at 1500 rpm for 5 minutes using Mistral 3000i centrifuge. 
6. 3 ml of the top layer (hexane) was transferred to clean glass tube.   
7. The samples were dried under a stream of nitrogen gas for 35-45 minutes.  The dried 
samples were kept overnight at –20 °C and resuspended the following day in 320 µl 
methanol. 
8. The α-tocopherol standards were prepared fresh.  Stock solution for α-tocopherol (1 
mg/ml) was prepared in 100% methanol.  The standards with concentration of 0, 0.1, 
0.25, 0.5, 1.0, 2.5, 5.0, 10.0, 25.0, and 50.0 µg/ml were prepared from stock solution. 
9. Once the samples were resuspended in methanol and the standards had been prepared, 
all samples and standards were filtered through 0.2 µM nylon acrodisc Gelman filters.  
Since the total volume was < 300 µl, small, glass inserts (Sun Brokers) were inserted 
in the vials to ensure that the autoinjector of the HPLC could easily attain the sample. 
Mobile phase and flow rate: 
100% HPLC grade methanol – filtered under vacuum using a 0.22 µM Nycaflo nylon 
membrane.  The mobile phase was degased for 20 minutes under vacuum after filtration.  
The flow rate of the mobile phase in the HPLC was 1 ml per minute.   
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HPLC analysis: 
1. The HPLC system included Shimadzu Systems Controller SCL-10A, 
Shimadzu Liquid Chromatograph (pump) LC-10AS, Shimadzu Spectrofluorometric 
Detector RF-551, Shimadzu UV Detector SPD-10A, Shimadzu Auto Injector SIL-
10A, Shimadzu Chromatopac CR501, and Column 25 cm x 4.6 mm packed with 5 
µm particle size C18 material. 
2. Fluorometric detector: 
α-tocopherol was measured with fluorometric detector.  The excitation was 205 nm 
and the emission was 350 nm.        
3. 50 µl of sample and standard were injected into the HPLC.   
Calculations: 
α-tocopherol (µg/g liver) = 
      α -tocopherol µg/ml        X     0.32 ml      X      3.6 ml     
    (based on linear regression)                      3.0 ml 
           g liver in 300µl of original WLH 
 
Isolation of nuclear extract: 
This procedure was performed as described in chapter 2. 
 
Electrophoretic mobility shift assay (EMSA): 
This assay was preformed as described in chapter 2. 
 
Western blotting: 
 The Western blotting to detect IKKs and IκBs were same as described in chapter 3 with 
minor modification: equal amount of protein were taken from each sample in a same 
group and mixed well. The pooled samples were used in Western blotting. 
 
BrdU and placental glutathione S-transferase i (PGSTi) immunohistostaining: 
The double immunostaining was carried out on the paraffin sections of liver. The staining 
procedure was same as described in chapter 2 until step 20, the rest procedure was 
performed as: 
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1. The slides were kept in normal goat serum (3 drops of stock normal goat serum 
mixed with 10 ml of 1 x automation buffer) at 37 C for 10 minutes.      
2. Excess serum was drained from slides and Avidin Block was applied to cover section, 
the slides were incubated for 15 minutes. 
3. The slides were dipped briefly in PBS, then covered with Biotin Block for 15 
minutes. 
4. The slides were drained and followed by covered with GSTpi antibody (the primary 
antibody was diluted in 40 fold of 1 x automation buffer). The slides were incubated 
in 37 °C for 30 minutes. 
5. The slides were rinsed in PBS for 2 changes, 5 minutes for each change. 
6. The biotinylated anti-rabbit IgG (1 drop of IgG was mixed with 3 drops of normal 
goat serum and 10 ml 1 x automation buffer) was applied to each slide, the slides 
were incubated at 37 °C for 15 minutes.  
7. The slides were rinsed in PBS for 2 changes, 5 minutes for each change. 
8. The slides were covered with ABC-AP (2 drops of A, 2 drops and 10 ml of 1 x 
automation buffer were mixed well, 2 drops each section). The slides were incubated 
at 37 °C for 15 minutes. 
9. The slides were rinsed in PBS for 2 changes, 5 minutes for each change. 
10. The slides were stained with Vector Red staining mix for 20 to 30 minutes. [The 
staining mix was made according to protocol from the vendor: for 5 ml 100 mM Tris-
HCl (pH8.2-8.5), 2 drops of reagent 1, 1 drop of levamisole, 2 drops of reagent 2 and 
2 drops of reagent 3 were added and mixed well]. 
11. The slides were monitored under a light microscopy to obtain the best staining. 
12. The slides were rinsed in assay buffer for 5 minutes. 
13. The slides were rinsed gently in tap water. 
14. The hemotoxylin counterstaining and the mounting were performed as described in 
chapter 2. 
 
Counting of BrdU-stained nuclei:  
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1. Cells that had incorporated BrdU were easily identified with brown nuclei. All 
hepatocytes in the PGST-positive foci were counted. For the non-foci area, at least 
3000 hepatocellular nuclei were counted randomly per slide. 
2. The labeling index was expressed as the percentage of number of labeled nuclei out 
of the total number of counted nuclei.  
 
Quantitation of altered hepatic foci: 
The number and volume of PGST-positive foci were measured using a computer 
digitizing system; the number of foci/cm3 (Saltykov method), foci/liver (Saltykov 
method), the mean focal volume (Saltykov method), and the volume fraction (Delesse 
method) were analyzed (Campbell et al. 1982; Campbell et al. 1986; Glauert 1991; 
Tharappel et al. 2002; Xu et al. 1998).   
 
Statistical analysis:   
Results were first analyzed by a two-way analysis of variance.  Individual differences 
between means were determined using the Bonferroni post hoc test.  The results were 
reported as means + standard error of mean (SEM).  The level of significance was p ≤ 
0.05. 
 
Results 
The relative liver weights (as percentage of body weight) were significantly 
increased in rats treated with PCBs at all levels of vitamin E, with the highest increase in 
PCB-77 groups (Table 4.2). Dietary vitamin E had no effect on the relative liver weight. 
The concentration of vitamin E in liver was increased by dietary vitamin E, with the 
highest level in those receiving PCB-77 (Figure 4.1). 
The number and volume of altered hepatic foci were quantified using placental 
glutathione S-transferase (PGST) as an immunohistochemical marker. The number of 
PGST-positive foci per liver and per cm3, as well as the mean focal volume and the total 
focal volume as a percentage of liver volume, were significantly increased in rats treated 
with PCB-77; the number of foci was increased 2-3 fold by PCB-153, but this effect was 
not statistically significant (Table 4.3). There was a slight but insignificant increase in the 
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number and volume of PGST-positive foci in PCB-77-treated animals by low level (10 
ppm) and high level (250 ppm) of dietary vitamin E compared to animals fed with 
medium level of vitamin E (50 ppm). The number and volume of PGST-positive foci 
were not changed by dietary vitamin E in rats treated with corn oil or PCB-153. 
 To measure cell proliferation in normal and PGST-positive hepatocytes, we 
quantified the labeling indexes after a 2-day infusion of BrdU using an Alzet osmotic 
pump. In nonfocal cells, PCB-77 significantly increased the BrdU index in rats fed with 
the low level (10 ppm) and medium level (50 ppm) of vitamin E (Figure 4.2), but not in 
animals fed with the high level of vitamin E (250 ppm), compared to the corn oil-treated 
controls. There was a 56% decrease in the labeling index in the PCB-77 group receiving 
high vitamin E (250 ppm), compared to the PCB-77 group receiving the medium level of 
vitamin E (p = 0.01). The labeling indexes were not significantly different in rats treated 
with PCB-153 compared to corn oil-treated controls. There was no significant difference 
among groups receiving any level of vitamin E in corn oil or PCB-153 groups. The 
labeling index was higher in focal cells than in nonfocal cells. PCB-77 significantly 
increased the labeling index in PGST-positive cells compared to corn oil-treated controls, 
the labeling indexes in PCB-77 groups receiving high level of vitamin E was 
insignificantly less than those receiving low level (p = 1.00) or medium level (p = 1.00) 
of vitamin E.  
 The DNA binding activity of NF-κB was measured with EMSA. In animals 
treated with PCB-77, there was a significant (p < 0.05) increase in the DNA binding 
activity of NF-κB (Figure 4.3). Rats fed the high level of vitamin E had a decrease in the 
PCB-77-induced DNA binding activity of NF-κB. In animals treated with PCB-153, the 
DNA binding activity of NF-κB was not significantly different from corn oil-treated 
controls. Dietary vitamin E had no effect on the DNA binding activity of NF-κB in corn 
oil or PCB-153 groups. 
 The levels of the IKK and IκB proteins were measured by Western blotting 
(Figure 4.4). There were no differences in the IKKα, IKKβ, and IKKγ proteins among 
any group receiving corn oil, PCB-77, or PCB-153, and groups receiving any level of 
dietary vitamin E. The high level of vitamin E (250 ppm) tended to decrease the IκBα 
and IκBβ proteins. PCB treatments had no effect on any of these proteins.  
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Table 4.2. Effect of dietary vitamin E and PCBs on body and liver weights 
             
Vitamin E Treatment Liver weight      Body weight Liver wt/Body wt(%) 
________________________________________________________________________ 
Low      corn oil   9.90 + 0.10      271.44 + 3.88        3.70 + 0.06  
  PCB-77 14.08 + 0.72*       240.78 + 5.12*       6.08 + 0.18* 
PCB-153 12.71 + 0.58*      268.50 + 6.24               4.71 + 0.13* 
Medium corn oil   9.11 + 0.42      266.22 + 3.81       3.39 + 0.12 
PCB-77 14.23 + 0.48*      238.78 + 2.99*       5.98 + 0.13* 
PCB-153 12.70 + 0.63*      274.75 + 6.62       4.46 + 0.11* 
High   corn oil   9.90 + 0.57      275.38 + 7.81       3.97 + 0.12 
  PCB-77 14.06 + 0.49*       239.78 + 5.23*             5.83 + 0.12* 
  PCB-153 12.28 + 0.34      269.57 + 5.67       4.66 + 0.08* 
________________________________________________________________________ 
Results are expressed as mean + SEM. Each group contained 9 animals (n = 9). *Values 
are significantly different from their respective controls treated with corn oil (p < 0.05).   
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Figure 4.1. α-tocopherol concentrations in liver tissues. Each group contained 9 animals 
(n = 9). Values represent mean + SEM. *Values are significantly different from 
respective controls treated with low level vitamin E (p < 0.05). #Values are significantly 
different from corn oil control groups (p < 0.05). 
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Table 4.3. Effect of vitamin E and PCBs on the induction of PGST-Positive Foci 
             
Vitamin E    Treatment      Foci/cm3         Foci/liver         Mean focal volume         Focal volume  
                      (mm3 x 10-3)          (% of liver volume) 
________________________________________________________________________ 
Low          corn oil     507 + 141   5008 + 1415         3.8 + 0.4      0.18 + 0.05  
        PCB-77       2120 + 420*    32250 + 7011*     125.6 + 81.6* 13.54 + 7.16*  
                     PCB-153     1137 + 230      14953 + 3164         5.1 + 1.0    0.47 + 0.10 
Medium       corn oil     561 + 96   5256 + 1101         3.4 + 0.2    0.21 + 0.05 
             PCB-77       1572 + 318*    22651 + 5115*       94.1 + 49.5* 11.67 + 6.01* 
               PCB-153       934 + 154      11531 + 2165         4.5 + 0.4    0.44 + 0.07 
High          corn oil         516 + 100         5882 + 1410         3.9 + 0.7    0.15 + 0.04 
         PCB-77       2660 + 946*     37906 + 13466*   128.0 + 90.3*  14.60 + 7.48* 
         PCB-153   1161 + 151       14261 + 2084         4.8 + 0.5    0.49 + 0.06 
________________________________________________________________________ 
Results are expressed as mean + SEM. Each group contained 9 animals (n = 9). *Values 
are significantly different from their respective controls treated with corn oil (p < 0.05). 
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Figure 4.2. Effect of vitamin E and PCBs on cell proliferation in focal and nonfocal 
hepatocyte. Rats were administrated BrdU by a 2-day infusion with Alzet osmotic pumps. 
Tissue sections were immunohistochemically stained for BrdU and labeling indexes were 
determined in PGST-positive foci and in normal hepatocytes. (A) Labeling indexes in 
normal hepatocytes. (B) Labeling indexes in PGST-positive hepatocytes. Each group 
contained 9 animals (n = 9). *Values are significantly different from other groups (p < 
0.05). a, b, groups with different number are significantly different (p < 0.05). 
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Figure 4.3. Effect of vitamin E and PCBs on the hepatic DNA binding activity of NF-κB.  
A. Relative NF- κB DNA binding activity was measured by EMSAs using a radiolabeled 
NF-κB oligonucleotide with liver nuclear extracts from individual rats. Each line contains 
extract from a single animal (5 µg). B. Quantitation of the NF- κB band as determined by 
subtracting background counts from the total counts in each NF- κB band. Each group 
contained nuclear extact from 4 animals (n = 4). Values represent means + SEM for 4 
animals. *Values are significantly different from their respective control groups treated 
with corn oil (p < 0.05).  
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Figure 4.4. Protein levels of cytosolic IκB and IKK. Each line contains equal amount of 
protein from 3 animals within the same group. 50 µg protein per line.  
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Discussion 
In this study, we tested the hypothesis that oxidative stress induced by PCBs may 
account for their tumor promoting activities, and therefore that the dietary 
supplementation of vitamin E would reduce formation of the PCBs-induced altered 
hepatic focal lesions. The hypothesis that formation of reactive oxygen species accounts 
for chemically induced hepatocarcinogenesis has been supported by many of the studies 
(Klaunig & Kamendulis 1999; Klaunig et al. 1995; Kolaja & Klaunig 1997). Vitamin E 
as the major antioxidant in liver has been tested for its role in carcinogenesis. Protective 
effects of vitamin E have been shown in skin, mammary and esophageal tumors (Burke et 
al. 2000; Hirose et al. 1986; Odeleye et al. 1992). Liver specific overexpression of the 
proto-oncogene c-myc and transforming growth factor-α (TGF-α) resulted in increased 
susceptibility to spontaneous liver tumors (Factor et al. 2000); dietary -tocopherol 
acetate supplementation (2000 mg/kg diet) decreased intracellular peroxides, 
chromosomal aberrations, dysplasia and hepatic adenoma incidence in these mice. 
Vitamin E decreased the hepatic tumor incidence in aflatoxin B1-treated mice (Nyandieka 
et al. 1990; Nyandieka & Wakhisi 1993; Nyandieka et al. 1989). Several studies have 
showed that increased dietary vitamin E decreased the number of altered hepatic foci or 
the focal volume with several different protocols (Moore et al. 1987) (Hendrich et al. 
1991; Klaunig & Kamendulis 1999; Kolaja et al. 1998; Makpol et al. 1997; Ogawa et al. 
1995; Stevenson et al. 1995). However, other studies have indicated an enhancement of 
carcinogenicity or no effect after vitamin E supplementation (Glauert et al. 1990; 
Kakizaki et al. 2001; Kolaja & Klaunig 1997; Lii et al. 1999; Lii et al. 1997). Kolaja et 
al. have shown that dietary vitamin E supplementation (450 mg/kg diet) for 60 days 
enhanced the growth of hepatic focal lesions after initiation with DEN (Kolaja & Klaunig 
1997). Glauert et al. found that dietary supplementation of α-tocopheryl acetate (500 
ppm) increased the number of altered hepatic foci and the incidence of tumors in female 
Sprague-Dawley rats treated with 0.025% ciprofibrate for 21 months (Glauert et al. 
1990). Studies also indicated no effect of vitamin E supplementation (5000 ppm) on the 
growth of the γ-glutamyl transpeptidase- and PGST-positive foci in phenobarbital-treated 
female Sprague-Dawley rats (Lii et al. 1999; Lii et al. 1997). Vitamin E supplementation 
showed no protection during DEN-induced hepatocarcinogenesis in transforming growth 
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factor-alpha (TGF-α) transgenic mice (Kakizaki et al. 2001). In the present study, both 
PCB-77 and PCB-153 increased the number and volume of PGST-positive foci, with 
PCB-77 exerting the strongest effect. This result is in agreement with previous studies in 
which hepatic tumor promoting activities of PCB congeners were examined (Dean et al. 
2002; Glauert et al. 1991; Silberhorn et al. 1990), including studies using the same 
protocol (Berberian et al. 1995; Tharappel et al. 2002). The strong promoting activity of 
PCB-77 can be explained by the facts that PCB-77 increased cell proliferation, and that 
the rate of cell proliferation in PGST-positive hepatocytes was higher than in normal 
cells. This result is in agreement with a previous study using the same protocol 
(Tharappel et al. 2002) and another study in which PCB-77 increased [3H]-thymidine 
incorporation in an initiation-promotion study using N-nitrosomorpholine as the initiator 
(Wolfle et al. 1988). 
PCB-77 increased cell proliferation and NF-κB binding activity in rats fed low 
(10 ppm) or medium (50 ppm) level of vitamin E. The high level of dietary vitamin E 
(250 ppm) caused a decrease in cell proliferation as well as in the NF-κB DNA binding 
activity in PCB-77-treated rat livers; however, the number and volume of PGST-positive 
foci were slightly increased in the same livers. This conflict can be explained by the 
different effects in normal cells and in PGST-positive cells: high level of dietary vitamin 
E significantly decreased the cell proliferation in normal hepatocytes (a 56% reduction, p 
= 0.01), while this decrease was much less in PGST-positive hepatocytes (a 22% 
reduction, p = 1.00), compared to rats receiving medium level of vitamin E; and the rate 
of cell proliferation in PGST-positive hepatocytes was much higher than that in normal 
hepatocytes in the same livers (2.05% in normal cells, 22% in PGST-positive cells).  
Hepatic concentration of α-tocopherol was affected by the dietary α-tocopherol 
level; and the level of α-tocopherol was increased by PCBs, with highest increase in rats 
treated with PCB-77. This increase in hepatic α-tocopherol has been reported earlier 
(Kato et al. 1989; Koremura et al. 1990; Twaroski et al. 2001a), and proposed as the 
result of acceleration of α-tocopherol absorption in presence of PCBs (Koremura et al. 
1990). In our study, pathological examination showed that PCBs administration caused 
fatty liver, with most severe effect in rats treated with PCB-77, which suggested that the 
increase of α-tocopherol in liver could be due to the accumulation of fat in livers. PCBs 
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have been shown to cause multiple effects on lipid metabolism (Azais-Braesco et al. 
1997; Yamamoto et al. 1994), such as hypercholesterolemia, differentiation of stellate 
cell and increased TBA-reactive substance (TBARS) in liver.   
The transcription factor NF-κB has been hypothesized to be important in tumor 
development (Karin et al. 2002) and in the tumor promotion activity of PCBs (Tharappel 
et al. 2002). The hepatic DNA binding activity of NF-κB was increased 1.5 – 2.5 fold by 
PCB-77, but not by PCB-153. In previous study using the same initiation-promotion 
protocol, NF-κB was activated more than 4 fold by both PCB-77 and PCB-153 
(Tharappel et al. 2002). The discrepancy between the two studies could be due to the 
different type of diets.  The level of antioxidants or the activity of the antioxidants could 
be different.  In our study, the vitamin mixture and the α-tocopherol acetate were ordered 
fresh, and the prepared purified diet was stored at -80°C until the day of use, whereas the 
chow diet used in the previous study was stored at room temperature until use.  The fat 
source could also be a factor; corn oil has been shown to activate NF-κB in Kupffer cells 
(Kono et al. 2000; Rusyn et al. 1999), although corn oil as vehicle did not show any 
effect on hepatic NF-κB activation in a 2-day study (data not published). The long-term 
effect of dietary corn oil on hepatic NF-κB activity is still unclear.  The purified diet used 
in our study contained solely corn oil stripped of vitamin E, whereas the fat sources in the 
unpurified diet used in the previous study were corn, soybean, fish oils and some animal 
fat (Purina Lab diet 5001).  Also, the non-nutritive chemicals in the unpurified diet could 
be activators or co-activators of NF-κB.  Thus, NF-κB seems to be sensitive to dietary 
factors when exposed to xenobiotics. Animals fed with lowest vitamin E (10 ppm) had 
the highest activity of NF-κB, while vitamin E supplementation decreased the NF-κB 
DNA binding activity, which has been shown by many other studies (Nakamura et al. 
1998; Slim et al. 1999). Many investigators believed that NF-κB is involved in tumor 
promotion because of its role in the regulation of cell cycle and anti-apoptotic process 
(Karin et al. 2002; Mayo & Baldwin 2000). Our study indicated that there was not a 
correlation between altered hepatic foci induction and NF-κB activation or cell 
proliferation in animals treated with PCB-77.  
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Chapter 5. Summary, conclusions,  and future studies 
 
Summary and conclusions 
 In the first study, we tested the hypothesis that PCBs can activate hepatic NF-κB 
and increase cell proliferation in rats. We used two PCB congeners in this study, the 
coplanar PCB-77 and the non-coplanar PCB-153. Our results showed that PCB-153 
caused a transient increase in hepatic NF-κB DNA binding activity and cell proliferation, 
with the most significant effect at 2 days after a single dose of PCB-153. But PCB-77 did 
not show any effect on either NF-κB DNA binding activity or cell proliferation. No 
synergistic effect on the activation of NF-κB was observed between the two PCBs, but 
there was a synergistic effect on hepatocyte proliferation between PCB-77 and PCB-153.   
 To understand the possible relationship between PCB-153-induced NF-κB DNA 
binding activity and cell proliferation and apoptosis, we used a mouse model that was 
deficient in the p50 subunit of NF-κB (p50-/-). In this study, a single dose of PCB-153 
increased hepatic NF-κB DNA binding activity and the rate of cell proliferation in wild 
type mice, but not in the p50-/- mice; the longer-term treatment with higher dose of PCB-
153 increased cell proliferation in p50-/- livers, but this increase was still less than that in 
the wild type mice. Usually the rate of apoptosis in livers of adult mice is very low, but 
p50-/- livers had more “spontaneous” apoptosis, and PCB-153 inhibited apoptosis in the 
p50-/- livers. Further studies on specific genes that could be involved in the regulation of 
cell cycle or apoptosis indicated a post-transcriptional regulation of cyclin D1 in the p50-
/- livers, based on the observation that p50-/- livers had less cyclin D1 protein than wild 
type, but the mRNA level of cyclin D1 was same in p50-/- and wild type mice. Studies on 
the Bcl-xL proteins showed that there was no difference between p50-/- livers and livers 
of wild type mice, and that Bcl-xL protein was not changed by PCB-153 treatment. 
 In the third study, we tested the hypothesis that the oxidative stress after PCBs 
exposure accounts for the tumor promoting activity of PCBs, and therefore that dietary 
supplementation of antioxidant would inhibit the PCBs-induced tumor promotion. The 
female rats were first initiated with a single dose of DEN, and then received 4 i.p. 
injections of corn oil, PCB-77 or PCB-153 (300 µmol/kg body weight, once every two 
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weeks). The rats were fed diets containing different levels of α-tocopherol acetate (10, 
50, or 250 ppm) during the promotion period. The placental glutathione S-transferase 
(PGST)-positive foci were used to quantify the preneoplastic lesions; both PCBs 
increased the number and volume of PGST-positive foci, with PCB-77 showing higher 
tumor promoting activity. PCB-77 caused an increase in hepatic NF-κB DNA binding 
activity and hepatocyte proliferation, and this increase was decreased by dietary 
supplementation of vitamin E, but the number and volume of PGST-positive foci were 
slightly, though insignificantly, increased in the same animals. The apparent conflict 
between the growth of altered hepatic focal lesions and the cell proliferation could be 
explained by the different effects in normal cells and in PGST-positive cells: the high 
level vitamin E significantly inhibited PCB-77-induced cell proliferation in normal 
hepatocytes, while this inhibitory effect was much less in the PGST-positive hepatocytes.    
 Overall, our studies have shown that a non-coplanar PCB can cause an increase in 
hepatic NF-κB DNA binding activity in rats and mice, and this increase in NF-κB 
activity contributes to the changes in cell proliferation and apoptosis. Dietary vitamin E 
supplementation did not show protective effects on the formation of altered hepatic foci 
(AHF) that were promoted by PCBs, although high level of vitamin E decreased PCBs-
induced hepatic NF-κB activation and cell proliferation. 
 
Future studies: 
 In the initiation-promotion study, the hepatic DNA binding activity of NF-κB was 
increased 1.5 – 2.5 fold by PCB-77, but not by PCB-153. In previous study using the 
same initiation-promotion protocol, NF-κB was activated more than 4 fold by both PCB-
77 and PCB-153 (Tharappel et al. 2002). The discrepancy between the two studies could 
be due to the different type of diets. The level of antioxidants or the activity of the 
antioxidants could be different.  In our study, the vitamin mixture and the α-tocopherol 
acetate were ordered fresh, and the prepared purified diet was stored at -80°C until the 
day of use, whereas the chow diet used in the previous study was stored at room 
temperature until use.  Also, the non-nutritive chemicals in the unpurified diet could be 
activators or co-activators of NF-κB.  Thus, NF-κB seems to be sensitive to dietary 
factors when exposed to xenobiotics. A study in our laboratory is underway to investigate 
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the differences of hepatocarcinogens on tumor promotion indices in rats receiving 
unrefined versus purified diets. 
 Interactions among different types of cells in liver when exposed to xenobiotics 
have drawn much attention. Peroxisome proliferators activate Kupffer cells (Rose et al. 
2000); the activated Kupffer cells then synthesize and secrete TNF-α or other cytokines, 
which stimulate neighboring hepatocytes to proliferate (Bojes et al. 1997). Inactivation of 
Kupffer cells with dietary glycine or methylpalmitate prevented peroxisome proliferator-
induced cell proliferation in rats (Rose et al. 1997a; Rose et al. 1997b). TNF-α mRNA 
was increased by WY-14,643 treatment in rats (Bojes et al. 1997; Rose et al. 1997b). 
Treatment with anti-TNF-α antibody also prevented WY-14,643-induced cell 
proliferation (Bojes et al. 1997). However, recent studies using TNF-α knockout mice or 
TNF-α receptor knockout mice have shown that TNF-α is not required for WY14,643-
induced hepatocyte proliferation (Anderson et al. 2001; Lawrence et al. 2001). Van Ess 
et al. recently showed that the TNF-α receptor is essential to the activation of NF-κB by 
phenobarbital in mice livers because of the fact that phenobarbital caused an increase in 
hepatic NF-κB DNA binding activity in wild type mice, but not in TNF (p55-/-/p75-/-) 
double receptor knockout mice (Van Ess et al. 2002).  To our knowledge, no one has 
investigated the role of Kupffer cells in mitogenesis by PCBs. Whether Kupffer cells or 
endogenous TNF-α are involved in PCB-induced hepatocellular proliferation is unclear. 
Studies to answer this question are underway in our laboratory: a short-term study 
performed on hepatocyte proliferation in rats fed 5% glycine and treated with PCB-153 to 
measure hepatocyte proliferation in the absence of Kupffer cell function; isolated rat 
Kupffer cells are treated with PCB-153 to see if they have increased NF-κB DNA 
binding activity or if they release cytokines in the media. Another study could be done to 
investigate the necessity of TNF-α pathway in PCB-153-induced hepatocyte 
proliferation: a short-term study measuring hepatocyte proliferation and NF-κB 
activation in TNF double receptor knockout mice treated with PCB-153.   
 Our study showed that p50-/- livers had less cyclin D1 protein than wild type, 
although they had same level of cylcin D1 mRNA. Assay using [35S]-methionine pulse 
labeling should be performed, if applicable, to elucidate whether this decreased protein is 
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due to translational down-regulation or decreased protein stability, or both. Cyclin D1 
turnover is governed by ubiquitination and proteasomal degradation, which are positively 
regulated by glycogen synthase kinase-3β (GSK-3β)-dependent phosphorylation on 
Threonine-286 (Diehl et al. 1998). Recent studies have indicated a crosstalk between 
GSK-3β and NF-κB. GSK-3β function has been shown to be required for NF-κB-
mediated anti-apoptotic response to TNF-α (Hoeflich et al. 2000). Disruption of the 
mouse GSK-3β gene causes severe liver degeneration during mid-gestation (Hoeflich et 
al. 2000), as observed in mice deficient in genes involved in NF-κB activation pathway 
(Beg et al. 1995; Li et al. 1999; Rudolph et al. 2000; Tanaka et al. 1999). The following 
studies indicated that GSK-3β regulates NF-κB at the level of the transcriptional 
complex, since the early steps leading to NF-κB activation and NF-κB DNA binding 
activity were not affected by loss of GSK-3β (Hoeflich et al. 2000; Schwabe & Brenner 
2002). The mechanism of possible cross-talk between GSK-3β and NF-κB is not clear, 
but studies have shown that recombinant GSK-3β can phosphorylate the p65 and p105 
subunits of NF-κB in cell-free systems (Demarchi et al. 2001; Schwabe & Brenner 
2002), and that GSK-3β can physically associate with p105 in living cells (Demarchi et 
al. 2001). How disruption of p50 results in decreased cyclin D1 protein as shown in this 
study need further investigation, and the interaction between NF-κB and GSK-3β is one 
of the possibilities. To test this, the first study need to be done is to test changes in 
mRNA and protein levels and the activity of GSK-3β between p50-/- and the wild type 
mice. If there is more GSK-3β protein or higher activity in the p50-/- livers, this would 
indicate a mutual regulation between p50 and GSK-3β. To further investigate the 
mechanism, immortalized cell lines from p50-/- and the wild type mice will be needed, 
and a functional p50 gene will be introduced into the p50-/- cell and the expression of 
GSK-3β and cyclin D1 will be checked. In addition, LiCl, the specific inhibitor of GSK-
3, has been shown to sensitize primary hepatocytes toward TNF-α-mediated apoptosis by 
decreasing transcription of NF-κB-dependent inducible nitric oxide synthase (iNOS) 
gene, but not the NF-κB activation or NF-κB DNA binding activity (Schwabe & Brenner 
2002). So LiCl can be used to investigate the effect of deficiency in GSK-3β activity on 
the cyclin D1 protein turnover. Also, our study showed that PCB-153 failed to induce 
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NF-κB DNA binding activity in the p50-/- livers, but it inhibited the apoptosis; it is 
questionable if PCB-153 affects NF-κB at the level of transcriptional complex. If the 
PCB-153 inhibited LiCl-mediated apoptosis, that would indicate PCB-153 may inhibit 
apoptosis through regulation of NF-κB transcriptional complex.     
The phosphorylation on Threonine-286 by GSK-3β not only mediates cyclin D1 
proteasomal degradation, but also promotes cyclin D1 nuclear export (Alt et al. 2000; 
Diehl et al. 1998). Cyclin D1 accumulates in the nucleus throughout G1 phase, but it 
relocates to the cytoplasm during the reminder of interphase (Baldin et al. 1993; Diehl et 
al. 1998). Thus, alterations in the intracellular distribution of cyclin D1 during the cell 
cycle may regulate cyclin D1/CDK4 function (Alt et al. 2000; Diehl et al. 1998). We 
examined cyclin D1 protein only in the whole liver homogenates. Thus, an 
immunohistochemical study using anti-cyclin D1 antibody has to be performed to 
compare the subcellular localization of cyclin D1 in wild type and p50-/- hepatocytes, 
and the effect of PCB-153. If there is any significant difference in the rate of cyclin D1 
turnover or the subcellular distribution of cyclin D1 between p50-/- livers and wild type, 
or after PCB-153 treatment, that would explain at least part of mechanisms by which NF-
κB may regulate cell proliferation after PCB-153 exposure.      
 NF-κB is an anti-apoptotic regulator, because the p65 null mice are embryonic 
lethal due to massive apoptosis in liver (Beg et al. 1995). In this study, p50-/- livers had 
more apoptosis than wild type, which also indicates the anti-apoptotic role of NF-κB. 
NF-κB regulates expression of certain anti-apoptotic genes, such as cIAP1, cIAP2 (Wang 
et al. 1998), TNF receptor-associated protein 1 and 2 (TRAF1, 2) (Wang et al. 1998), and 
Bcl-2/Bcl-xL (Lee et al. 1999; Tamatani et al. 1999; Wang et al. 1999). In this study, the 
protein level of Bcl-xL was not changed by PCB-153 in both 2-day and 21-day studies, 
and p50-/- livers had same level of Bcl-xL as the wild type. Which gene(s) is involved in 
the increased apoptosis in p50-/- livers is not clear in this study. A study using 
Affymetrix microarray is underway in our laboratory to compare the change in RNA 
level of genes in p50-/- and wild type mice in response to PCB-153 treatment; results 
from this microarray study may indicate genes that may be involved in the changes of 
cell proliferation and apoptosis by PCB-153 treatment.     
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Last, the role of NF-κB activation in hepatic tumor promotion by PCBs needs to 
be determined. Our data have shown that in livers deficient in the p50 subunit of NF-κB, 
the cell proliferation was not increased by PCB-153 in the short-term (2 days) study, and 
was increased in the longer-term (21 days) study by higher dose of PCB-153, but this 
increase was less than that observed in wild type mice. Alteration of cell proliferation and 
apoptosis has been proposed to be one of the mechanisms of carcinogenesis by tumor 
promoters. Despite all the data available, it is still a question whether the deficiency in 
p50 subunit of NF-κB can be protective in PCBs-induced tumorigenesis. To answer this 
question, an initiation-promotion study using p50-/- mice needs to be done. A PCB 
mixture and a specific congener have been shown to have liver tumor promoting activity 
in mice: Anderson et al. have shown that PCB mixture Aroclor 1254 increased the 
incidence of liver adenomas in Swiss NIH:NCr mice initiated with N-
nitrosodimethylamine (NDMA) (Anderson et al. 1994); Kobush et al. have shown that 
PCB-77 treatment in N-nitrosomorpholine (NNM)-initiated B6C3F1 mice led to a 
decrease in the number of G6Pase-positive and –negative foci (Kobusch et al. 1989). On 
the other hand, the volume and the mean diameter of the G6Pase-positive and –negative 
foci were increased by PCB-77. Therefore, p50-/- mice could be used in an initiation-
promotion study to examine the formation of altered hepatic foci or liver tumors with 
PCBs treatment. If the p50 -/- mice develop fewer hepatic tumors or AHF, we could 
confirm the protective effect of the deletion of p50 subunit in hepatic carcinogenesis by 
PCBs.  
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